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ABSTRACT 
Chlamydia pneumoniae is a Gram-negative bacterium, which has a unique intracellular devel-
opmental cycle for replication inside host cells. C. pneumoniae infects the respiratory tract 
and is a common cause of upper respiratory tract infections as well as bronchitis and atypical 
pneumonia, which may be mild or life-threatening. Similarly to all chlamydial species, C. 
pneumoniae has a tendency to cause chronic infections, which may lead to severe disease se-
quelae, such as chronic pulmonary diseases and atherosclerosis. In an experimental C. pneu-
moniae infection model, C. pneumoniae and chronic inflammation persist in mouse lung. 
Among the individual chlamydial antigens, chlamydial Heat shock protein 60 (cHsp60) is 
associated with chronic diseases. The immune response against cHsp60 and, further, the de-
velopment of autoimmunity against host Hsp60 are associated with a chronic inflammatory 
disease, namely atherosclerosis. In the prevention of cardiovascular diseases, lipid-lowering 
statin therapies are widely used. They inhibit the rate-limiting step in the mevalonate pathway 
and cholesterol biosynthesis and have been shown to have antimicrobial effects. 
In the present study, a mouse model for C. pneumoniae infection was used. Specifically, 
the technical aspects, the pulmonary infection, the development of atherosclerotic lesions and 
Hsp60 autoimmunity, and the possible effect of simvastatin treatment on C. pneumoniae in-
fection were studied. Mice were infected with C. pneumoniae and, in some experiments, fed a 
diet with some cholesterol supplementation or a high-fat diet. 
One of the most important findings of the present study was that the host cell components in 
the C. pneumoniae inoculum may induce a weak inflammatory response. This may affect the 
course of infection by, for instance, reactivating a culture-negative infection. It was also 
shown that chronic C. pneumoniae infection led to the development of a humoral Hsp60 auto-
immune response along with the development of initial aortic atherosclerotic lesions. The 
Hsp60 autoimmune response developed after repeated C. pneumoniae exposures and was ex-
aggerated if the mice were also fed a cholesterol-supplemented diet. In addition, treatment 
with simvastatin was shown to exhibit an antichlamydial effect in vivo. The effect was seen as 
diminished chlamydial growth in the lungs. 
Keywords: Chlamydia pneumoniae; Chlamydophila pneumoniae; Mice; Models, animal; Dis-
ease models, animal; Pneumonia; Pulmonary infection; Hsp60 autoimmune response; Chronic 
infection; Arteriosclerosis; Atherosclerosis; Simvastatin
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TIIVISTELMÄ 
Chlamydia pneumoniae on Gram-negatiivinen bakteeri, jolla on solunsisäinen lisäänty-
miskierto. C. pneumoniae infektoi hengitysteitä ja on yleinen ylähengitystieinfetioiden, ja 
myöskin bronkiitin ja atyyppisen pneumonian aiheuttaja. Infektio voi olla lievä tai hen-
genvaarallinen. C. pneumoniae:lla kuten muillakin klamydialajeilla on taipumus aiheuttaa 
kroonisia infektioita, jotka voivat johtaa vakavimpiin jälkiseurauksiin, kuten kroonisiin 
keuhkotauteihin ja ateroskleroosiin. Kokeellisessa infektiomallissa, C. pneumoniae ja 
krooninen tulehdus persistoivat hiiren keuhkoissa. Yksi tärkeimmistä klamydian antigee-
neistä, joka on yhdistetty kroonisiin tautimuotoihin, on klamydian 60kD:n stressiproteiini 
Hsp60. Sitä vastaan syntyvä immuunivaste ja mahdollinen autoimmuunivaste isännän 
omaa Hsp60:a vastaaan voivat osallistua kroonisen tulehdustaudin, ateroskleroosin kehit-
tymiseen. Sydän- ja verisuonitautien ehkäisyssä ja hoidossa käytetään laajasti kolesterolia 
alentavia statiineja. Ne inhiboivat kynnysreaktiota mevalonaatti-synteesipolulla ja kole-
sterolin biosynteesissä ja niillä on havaittu olevan antimikrobisia vaikutuksia. 
Tässä tutkimuksessa käytettiin hiirimallia C. pneumoniae infektiolle. Tutkimuksen 
kohteena olivat hiirimallin tekninen suorittaminen, keuhkoinfektio ja siihen vaikuttavat 
tekijät, ateroskleroosin ja autoimmuunivasteen kehittyminen Hsp60:lle, sekä kolesteroli-
lääke simvastatiinin mahdollinen vaikutus C. pneumoniae infektioon. Hiiret infektoitiin 
nenän kautta C. pneumoniae:lla, ja joissakin kokeissa käytettiin rehua, jossa oli ylimää-
räinen annos kolesterolia tai rasvaa. 
Tutkimuksen yksi tärkeimmistä tuloksista oli, että infektoinnissa käytettävän C. pneu-
moniae -preparaatin sisältämät isäntäsolujen rippeet saattavat aiheuttaa lievää tulehdusreak-
tiota. Tämä voi vaikuttaa infektion kulkuun mm. reaktivoimalla piilevän infektion. Lisäksi 
osoitettiin, että krooninen C. pneumoniae infektio johtaa Hsp60-autovasta-aineiden lisään-
tymiseen, sekä alkuvaiheessa olevien ateroskleroottisten plakkien kasvamiseen. Hsp60 au-
toimmuunivaste kehittyi toistuvien C. pneumoniae infektioiden myötä, ja voimistui mikäli 
hiiriä syötettiin rehulla, jossa oli kolesterolilisä. Simvastatiini-hoidolla havaittiin lisäksi 
olevan klamydian kasvua hillitsevä vaikutus, joka näkyi vähentyneenä klamydian lisäänty-
misenä hiiren keuhkoissa. 
Avainsanat: Chlamydia pneumoniae; Keuhkoklamydia; Hiirimalli; Keuhkokuume; Keuh-
koinfektio; Hsp60 autoimmuunivaste; Krooninen infektio; Ateroskleroosi; Simvastatiini 
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AAA  abdominal aortic aneurysm 
AM  alveolar macrophage 
ApoE-KO  Apolipoprotein E knockout 
bp  base pair 
CAD  coronary artery disease 
CAP  community-acquired pneumonia 
cHsp60  chlamydial heat shock protein 60 
CO2  carbon dioxide 
COPD  chronic obstructive pulmonary disease 
CRP  C-reactive protein 
DMSO  dimethylsulfoxide 
EB  elementary body 
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Ig  immunoglobulin 
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IL  interleukin 
i.n.  intranasal 
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i.p.  intraperitoneal 
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K6  Kajaani 6, Chlamydia pneumoniae isolate 
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LBP  lipopolysaccharide-binding protein 
LDL  low-density lipoprotein 
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1 Review of the literature 
1.1 Bacterial pathogens and the respiratory tract 
The human respiratory tract is divided into the upper and lower airways. The ascending 
bronchi narrow through dichotomous branching, and only particles smaller than 10 μm in 
diameter are able to reach the lung along with the airflow, and particles smaller than 3-5 
μm have direct access into the bronchioles. 
The bacteria causing respiratory infections may be part of the normal flora in the up-
per respiratory tract or may be acquired from the environment within aerosols or droplets. 
In the respiratory tract, bacteria are in contact with the ciliated epithelium, which at-
tempts to push the trapped particles upward within mucus. The alveoli are lined by a thin 
layer of alveolar lining fluid, which contains soluble immune molecules, complement, 
collectins (e.g. surfactants A and D), and immunoglobulins. Soluble factors and cells of 
the innate immune system (lymphocyte-independent immunity) serve as the first-line 
defence against invading microbes. Dendritic cells are present in the submucosa of the 
nasopharynx, trachea and bronchial tree, and alveolar macrophages (AM) within the al-
veoli, with approximately one AM per alveolus. In addition to the immune cells in tis-
sues, those residing in blood, i.e. monocytes and phagocytic neutrophils, are rapidly ex-
travasated from blood when needed in defence against pulmonary infection. Blood-
derived monocytes differentiate into macrophages in tissues. Monocyte and neutrophil 
cytokine signalling activates other immune cells. Cytokine signalling also induces the 
secretion of acute phase proteins as C-reactive protein (CRP). For innate immune recog-
nition and subsequent phagocytosis and/or pro- or anti-inflammatory activation, pre-
exposure is not needed, but molecular detection is based on structural divergence between 
procaryotes and eucaryotes. Procaryotes have conserved motifs, called pathogen-
associated molecular pattern, e.g. lipopolysaccharide (LPS) and lipoteichoid acid. Im-
mune cells recognize these through pattern recognition receptors, which are surface or 
cytosolic molecules, e.g. CD14, toll-like receptors (TLR), cytosolic nucleotide-binding 
oligomerization domain (Nod) receptors, LPS-binding protein (LBP), and mannose-
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binding lectin (MBL) (Aderem and Ulevitch, 2000; Gordon and Read, 2002). Innate im-
mune responses activate lymphocyte-dependent immunity, i.e. T- and B-cell responses. 
If a pathogen is able to reach the alveoli and remains alive, it is widely dispersed onto 
the epithelium and may disseminate from one alveolus to another through, for instance, 
alveolar pores (pores of Kohn). Further, though there are effective anti-infective mecha-
nisms to protect the organism against airborne pathogens entering the circulating blood in 
gas-exchanging areas, common bacteria causing pneumonia can also be detected in circu-
lation. 
1.2 C. pneumoniae diseases of the respiratory tract 
1.2.1 Acute respiratory diseases 
The outcome in host-microbe interaction, in general, is influenced by microbial and host-
related factors. The outcome and possible damage vary between different microbes and 
hosts and between a certain microbe and its host over time, and the process keeps chang-
ing continuously (Fig. 1). (Casadevall and Pirofski, 1999). In commensalism and symbio-
sis, no damage to the host occurs, and in symbiosis, both benefit from the interaction. 
Colonization is a continuum of damage, which may progress to disease or persistence. In 
persistence, the host suffers continuous damage, and microbial persistence may be reacti-
vated into overt disease. (Casadevall and Pirofski, 2000). 
HOST-MICROBE
CONTACT INFECTION
SYMBIOSIS
COMMENSALISM
COLONIZATION
PERSISTENCE
DISEASE
Fig. 1. Outcome of host-microbe interaction in infection. If the microbe is not eradicated, 
infection may result in colonization, disease, or commensalism. Colonization may further 
develop into persistence (chronicity/latency) and/or disease, and commensalism into symbiosis 
or disease if sufficient damage ensues from the interaction. Modified from (Casadevall and 
Pirofski, 2000). 
C. pneumoniae, which spreads through the respiratory tract, is transmitted from person to 
person relatively inefficiently (Kleemola et al., 1988; Grayston et al., 1990; Aldous et al., 
1992; Grayston et al., 1993), but it is still assumed that almost all people get infected with 
it at least once during their lifetime. Adults have 60-70 % seroprevalence, and men have 
higher seroprevalence than women (Grayston, 1992). The outcome of C. pneumoniae
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infection in the respiratory tract may vary from asymptomatic nasopharyngeal carriage 
(Hammerschlag, 2004) through mild upper respiratory tract infections, sinusitis, 
pharyngitis, and otitis media to lower respiratory tract infections such as bronchitis 
(Grayston, 1992) and life-threatening pneumonia (Troy et al., 1997), and even severe 
systemic diseases have been reported (Grayston, 1994). As the high prevalence rates sug-
gest, most (70 %) C. pneumoniae infections remain asymptomatic or mild, while a 
smaller proportion (30 %) result in more severe diseases (Hahn et al., 2002). Although 
some typical features exist, e.g. prolonged cough, (Miyashita et al., 2003) and some pa-
tient groups may be more likely to have C. pneumoniae disease than others, there are no 
specific clinical findings associated with C. pneumoniae respiratory infections (Grayston, 
1992). One study showed that the highest predictive values for C. pneumoniae etiology 
was found in patients from nursing homes, with low CRP levels, non-productive cough, 
and normal urine analysis (Socan et al., 2004). In industrialized countries, community-
acquired pneumonia (CAP) is the most common serious infectious disease. In Finland, 
the most common etiological agent of bacterial pneumonia, Streptococcus pneumoniae,
causes 40-50 % of all CAP cases, while atypical bacteria, Mycoplasma pneumoniae and 
C. pneumoniae, cause 10-20 % of pneumonia cases during interepidemic periods 
(Jokinen et al., 2001). C. pneumoniae is evidently not an important cause of severe infec-
tions in small children (Chirgwin et al., 1991; Grayston, 1994), though severe pulmonary 
involvement has been reported to occur in otherwise healthy children and in adults 
(Hammerschlag, 2004), but most commonly, it causes mild pneumonias in school-aged 
children and healthy adolescents, e.g. college students and military conscripts (Kleemola 
et al., 1988; Grayston et al., 1993). 
In C. pneumoniae disease, the damage is both pathogen- and host-mediated, and im-
mune defence evidently plays a significant role in directing the respiratory outcome and 
cardiovascular dissemination. C. pneumoniae reinfections or recurrent infections may 
occur at short intervals. In fact, at least part of recurrent infections may actually be reac-
tivations of chronic infections (Kleemola et al., 1988; Ekman et al., 1993). C. pneumo-
niae may also persist in the lungs of subjects with normal lung funtion (Wu et al., 2000; 
Kotsimbos et al., 2005). Chronic quiescent infection is possibly reactivated when appro-
priate, e.g. immunosuppressive, conditions emerge, as has been reported during hospitali-
zation or in experimental animals on immunosuppressive cortisone treatment (Grayston 
et al., 1989a; Malinverni et al., 1995a; Laitinen et al., 1996). 
1.2.2 Chronic pulmonary diseases 
Evidently, persistent C. pneumoniae infection in the lungs contributes to several chronic 
pulmonary diseases (Laurila et al., 1997b), asthma and chronic obstructive pulmonary 
disease (COPD) being the most intensively studied. Adult-onset asthma, wheezing, asth-
matic bronchitis, more severe asthma, and in asthmatic children, acute wheezing episodes 
and frequent exacerbations may be C. pneumoniae-associated  (Hahn et al., 1991; Emre 
et al., 1994; Hahn et al., 1996; Cunningham et al., 1998; Black et al., 2000). Polymor-
phism of the host MBL gene seems to affect the association between C. pneumoniae and 
asthma (Nagy et al., 2003). COPD and its acute exacerbations may also be C. pneumo-
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niae-associated (Blasi et al., 1993; von Hertzen et al., 1995; von Hertzen et al., 1996; von 
Hertzen et al., 1997; Wu et al., 2000). Other chronic lung processes whose serological 
associations with C. pneumoniae infection have been studied include sarcoidosis 
(Puolakkainen et al., 1996) and lung cancer (Laurila et al., 1997a; Jackson et al., 2000; 
Littman et al., 2005). 
1.3 C. pneumoniae 
1.3.1 History and taxonomy 
C. pneumoniae was first found to be a human pathogen during mild pneumonia epidem-
ics in Finland, as demonstrated by the antibody response against the first C. pneumoniae
isolate TW-183 (Saikku et al., 1985). Later, respiratory tract–derived isolates were ob-
tained from patients during acute respiratory tract infection (Grayston et al., 1986). The 
two first isolates (TW-183 and AR-39) were originally given the strain name TWAR 
(Grayston et al., 1986). They were serologically unique, and less pathogenic in mice than 
the other C. psittaci and C. trachomatis strains. Based on their morphology and staining 
with iodine (C. psittaci inclusions do not stain with iodine contrary to C. trachomatis
inclusions), however, they were considered as C. psittaci (Kuo et al., 1986). Eventually, 
in 1989, the strain TWAR was classified as a new species based on elementary body (EB) 
ultrastructure (Chi et al., 1987), DNA analysis (Campbell et al., 1987; Cox et al., 1988), 
and serology (Kuo et al., 1986) and given the name C. pneumoniae (Grayston et al., 
1989b).
In the order Chlamydiales, only the family Chlamydiaceae and its pathogenic Chla-
mydia species - C. pneumoniae, C. psittaci and C. trachomatis - were identified. Re-
cently, environmental species with similar characteristics - obligate intracellular growth 
and unique developmental cycle - belonging to three more families, Parachlamydiaceae,
Simkaniaceae and Waddliaceae, have been recognized, and the possibility of emerging 
pathogens within these families has been recognized (Amann et al., 1997; Kahane et al., 
1998; Everett et al., 1999; Rurangirwa et al., 1999; Friedman et al., 2003). Environmental 
chlamydiae may have twice as large genomes as pathogenic chlamydiae, and although 
there is little evidence of recent lateral gene acquisition, they contain the same virulence 
factors as pathogenic chlamydiae (Horn et al., 2004). In 1999, based on 16S and 23S ri-
bosomal RNA (rRNA) sequences, the family Chlamydiaceae, which contains the patho-
genic chlamydiae, was taxonomically reclassified (Everett et al., 1999), and one genus in 
the former, namely Chlamydia, was divided into two genera: Chlamydia and Chlamydo-
phila (Fig. 2). C. pneumoniae was then renamed as belonging to the genus Chlamydo-
phila. However, chlamydiae are still considered to constitute a unique group of bacteria 
that should not yet be separated (Schachter et al., 2001), and the original name Chlamy-
dia pneumoniae is used alongside the proposed new one, and actually even more fre-
quently (PubMed, year 2004, Chlamydia pneumoniae or Chlamydophila pneumoniae as a 
title/abstract word: 238 vs. 42, respectively). In addition, the new classification also iden-
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tified the animal pathogen species in the Chlamydiaceae family (Fig. 2). Recently, the 
previous belief that C. pneumoniae is only a human pathogen, has changed. As a possible 
disease reservoir, C. pneumoniae infections do occur in wild and domestic animals. Natu-
ral hosts include horse, koala and amphibians (reviewed in (Longbottom and Coulter, 
2003)) as well as reptiles (Bodetti et al., 2002) and dogs (Sako et al., 2002). Varying 
clinical signs, including atherosclerosis, have been reported in these animals, too. 
Fig. 2. New and former classification of Chlamydiaceae. The most common hosts for each 
species are listed. For details concerning the genus name of C. pneumoniae, see the text. Modi-
fied from (Bush and Everett, 2001). 
1.3.2 Cell biology 
The complete C. pneumoniae genome size is 1.23x106 base pairs (bp) (Kalman et al., 
1999), and the interstrain identity between the thus far sequenced strains (AR-39, J138, 
CWL029 and TW-183) is >99.9% (Read et al., 2000a; Shirai et al., 2000). The chlamy-
dial nucleoid consists of the chromosome and of two eucaryotic histone-like proteins 
(Hackstadt et al., 1991). Some biovars may contain a plasmid (Everett et al., 1999), and a 
4524-nucleotide single-stranded DNA bacteriophage (?Cpn1) has been found in the 
strain AR39 but not in the other strains studied (Read et al., 2000a; Read et al., 2000b). 
Chlamydiae are strictly intracellular bacteria that multiply within inclusions in host cells 
and avoid lysosomal fusion (Moulder, 1991; Al-Younes et al., 1999). Chlamydial parti-
cles are non-motile and have a large periplasmic space (Fig. 3.a.). The pointed end of the 
pear-shaped EB particle may be the first part to contact the host cell (Kuo et al., 1988). 
The cell wall of C. pneumoniae resembles that of gram-negative bacteria, and the outer 
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membrane contains LPS. Chlamydiae have genes for peptidoglycan synthesis, but the 
issue of whether peptidoglycan exists is controversial (Ghuysen and Goffin, 1999). Sys-
tematic genome studies of C. pneumoniae surface proteins (outer membrane, periplasmic 
and inner membrane proteins) have identified 53 proteins, which include a major outer 
membrane protein (MOMP)/outer membrane protein A (OmpA), PorB, a 76-kDa protein 
homolog, 11 proteins of the polymorphic membrane protein (Pmp) family, a cysteine-rich 
60-kDa protein encoded by omcB (Omp3), a 9-kDa cysteine-rich outer membrane com-
plex lipoprotein OmcA (Omp2), DnaK and Mip-like proteins, hypothetical protein, and 
type-three secretion system  proteins (Montigiani et al., 2002), which may provide a di-
rect connection between chlamydial particles and the host cell cytoplasm (Miyashita et 
al., 1993). Several molecules are involved in the attachment and subsequent endocytosis 
of chlamydiae, e.g. the host cell’s heparan sulfate-like glycosaminoglycan (Wuppermann 
et al., 2001), and the cholesterol-containing lipid rafts on the host cell plasma membrane 
(Stuart et al., 2003). Once internalized within an inclusion, C. pneumoniae EBs reorgan-
ize into vegetative reticulate bodies (RBs), which multiply by binary fission during their 
logarithmic growth and occasionally possibly by budding (Wolf et al., 2000) (Fig. 3.b.). 
At the end of the cycle, RBs reorganize back into more condensed and rigid EBs, and 
oxidation of the outer membrane cysteine-rich proteins takes place. Both nonlytic and 
lytic release of infectious progeny occurs (Gieffers et al., 2002). The ATP required for C. 
pneumoniae growth is derived both from the host cell (ATP/ADP translocase) and from 
chlamydial de novo synthesis (Read et al., 2000a). 
A    B  
Fig. 3. A) Scanning electron micrograph of C. pneumoniae AR-39 EBs inside an inclusion in a 
HeLa cell. The arrow points to the large periplasmic space between the outer membrane and 
the cytoplasmic membrane of EB at the breaking point. B) Transmission electron micrograph 
of C. pneumoniae AR-39 inclusion in a HeLa cell 60 hours after infection. Both RBs and EBs 
are present. (Wolf et al., 2000). 
1.3.3 Experimental in vivo models for C. pneumoniae infection 
Mouse is most commonly used in experimental C. pneumoniae in vivo studies (Tables 1 and 
2). In the first reported study, Swiss Webster mice were infected intranasally (i.n.), intrave-
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nously (i.v.), or intracerebrally (i.c.), and the organism was recovered from different tissues: 
from the brain after an i.c. challenge, from the lungs after an i.n. challenge, and from the 
spleen, liver, and lungs after an i.v. challenge. In the same tissues, inflammatory reactions 
were detected by histology (Kuo et al., 1986). The course of mouse lung infection after i.n. 
inoculation during primary and reinfection was later described in more detail (Kaukoranta-
Tolvanen et al., 1993; Yang et al., 1993), and i.n. infection became the most commonly used 
route of challenge in lung infections as well as later in atherosclerosis models. In primary 
infection, culture positivity in the lungs lasts for a few weeks. Inflammation, as detected 
histologically, persists in the lungs beyond the culture-positive period. After reinfection, the 
culture-positive period is shorter, and the inflammatory reaction is exaggerated. Variations 
occur between different mouse strains, C. pneumoniae isolates, and challenging doses. The 
use of more sensitive methods, such as polymerase chain reaction (PCR), in detecting C. 
pneumoniae in animal tissues has extended the C. pneumoniae-positive period to several 
months after the last challenge. Clinical signs in mice and other species are usually scarce, 
unless a high inoculation dose is given. 
Table 1. C. pneumoniae studies in mouse models. 
Study topic Reference Infection Cpn Mouse 
  route strain strain 
Infection course (Kuo et al., 1986) i.n., i.c., i.v. AR-39 
TW-183 
Swiss Webster 
 (Kishimoto, 1990) i.n. TW-183 ICR 
 (Kaukoranta-Tolvanen et al., 1993) i.n. TW-183 
K6 
Helsinki 12 
Swiss Webster 
NIH/S 
BALB/c 
 (Yang et al., 1993) i.n. AR-39 Swiss Webster 
ICR 
BALB/cAnN 
C57BL/6N 
B6C3F1 
C3H/HeN 
 (Kimura, 1994) i.n. TW-183 IHC 
 (Yang et al., 1994) i.n. AR-39 Swiss Webster 
 (Kaukoranta-Tolvanen et al., 1995) i.n. K6 NIH/S 
 (Malinverni et al., 1995a) i.n. AR-39 Swiss Webster 
 (Yang et al., 1995) i.n., i.v., s.c. AR-39 Swiss Webster 
 (Laitinen et al., 1996) i.n. K6 NIH/S 
 (Moazed et al., 1998) i.p. AR-39 C57BL/6J 
 (Erkkilä et al., 2002) i.n. K6 NIH/S 
 (May et al., 2003) i.v. CM1 C57BL/6J 
 (Shi et al., 2003) i.n., i.v. CWL-029 Icr 
 (Little et al., 2005) i.n. AR-39 BALB/c 
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Technique (Erkkilä et al., 2000) i.n. K6 
K7 
NIH/S 
C57BL/6J 
Atherosclerosis (Moazed et al., 1997) i.n. AR-39 ApoE-KO 
C57BL/6J 
 (Hu et al., 1999) i.n. AR-39 LDLR-KO 
 (Moazed et al., 1999) i.n. AR-39 ApoE-KO 
 (Blessing et al., 2000) i.n. AR-39 C57BL/6J 
 (Liu et al., 2000) i.n. AR-39 LDLR-KO 
 (Liuba et al., 2000) i.n. IOL 207 ApoE-KO 
 (Aalto-Setälä et al., 2001) i.n. K7 ApoE-KO 
 (Blessing et al., 2001) i.n. AR-39 C57BL/6J 
 (Burian et al., 2001a) i.n. TWAR BALB/c 
 (Burnett et al., 2001) i.n. na ApoE-KO 
 (Caligiuri et al., 2001) i.n. na C57BL/6J 
ApoE-KO 
 (Rothstein et al., 2001) i.n. A-03 ApoE-KO 
 (Blessing et al., 2002a) i.n. AR-39 C57BL/6J 
 (Ezzahiri et al., 2002) i.p. TWAR2043 ApoE3-Leiden 
 (Chesebro et al., 2003) i.n. AR-39 eNOS-/- 
iNOS-/- 
 (Ezzahiri et al., 2003) i.p. TWAR2043 LDLr/ApoE-/- 
 (Erkkilä et al., 2004) i.n. K7 C57BL/6JBom 
 (Sharma et al., 2004) i.n. AR-39 LDLR-KO 
Lipids (Tiirola et al., 2002) i.n. K7 NIH/S 
Alzheimer (Little et al., 2004) i.n. 96-41 BALB/c 
Immunology (Peterson et al., 1996) i.p. TW-183 BALB/c 
C57BL/6 
 (Penttilä et al., 1998b) i.n. K6 NIH/S 
BALB/c 
C57BL/6J 
 (Penttilä et al., 1998a) i.n. K6 BALB/c 
 (Peterson et al., 1998) i.n. TW-183 
2043
CM-1 
Swiss Webster 
 (Penttilä et al., 1999) i.n. K6 BALB/c 
nu/nu 
 (Rottenberg et al., 1999) i.n. K6 C57BL/6 
BALB/c 
multiple KOs 
 (Geng et al., 2000a) i.n. TW-183 BALB/c 
129 
G129
 (Murdin et al., 2000) i.n. AR-39 BALB/c 
 (Pal et al., 2000) i.n. TW-183 129sv 
Nramp1d 
 (Penttilä et al., 2000) i.n. K6 BALB/c 
 (Rottenberg et al., 2000) i.n. K6 C57BL/6 
multiple KOs 
 (Svanholm et al., 2000) i.n. K C57BL/6 
multiple KOs 
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 (Vuola et al., 2000) i.n. K6 BALB/c 
C57BL/6JBom 
 (Bandholtz et al., 2002) i.n. K6 C57BL/6 
multiple KOs 
 (Airaksinen et al., 2003) i.n. K6 BALB/c 
 (Burian et al., 2003) i.n. TW-183 BALB/c 
+KO 
 (Mueller et al., 2004) i.n. HK Swiss Webster 
C3H/HeN 
C3H/HeJ 
TLR2+/+, -/- 
 (Mygind et al., 2004) i.n. na C57BL/6J 
 (Penttilä et al., 2004) i.n. K6 BALB/c 
 (Rothfuchs et al., 2004) i.n. K6 C57BL/6 
multiple KOs 
Antibiotics (Nakata et al., 1994) i.n. K6 
IOL 207 
MHC-ICR 
 (Malinverni et al., 1995b) i.n. AR-39 Swiss Webster 
 (Masson et al., 1995) i.n. TW-183 NIH/S 
BALB/c 
MF1 
C3H/He 
 (Wolf and Malinverni, 1999) i.n. AR-39 NMRI 
 (Bin et al., 2000) i.n. AR-39 NMRI 
 (Törmäkangas et al., 2004b) i.n. K7 C57BL/6J 
 (Törmäkangas et al., 2004a) i.n. K7 C57BL/6J 
 (Blessing et al., 2005) i.n. AR-39 ApoE-KO 
Abbreviations used in this table: i.n.=intranasal; i.c.=intracranial; i.v.=intravenous; 
s.c.=subcutaneous; i.p.=intraperitoneal; Cpn=C. pneumoniae; na=not assessed; ApoE-
KO=ApoE knockout; LDLR-KO=LDL receptor knockout. 
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Table 2. Other C. pneumoniae animal model studies. 
Animal Reference Infection Cpn Study topic 
species  route strain  
Monkey (Kuo et al., 1986) conjunctiva TW-183 Infection course 
 (Holland et al., 1990) several mucosal sites TW-183 Infection course 
Baboon (Bell et al., 1989) i.t., several mucosal sites AR-39 Infection course 
Rabbit (Moazed et al., 1996) i.n., i.t. AR-39 Atherosclerosis 
 (Fong et al., 1997) nasopharynx VR1310 Atherosclerosis 
 (Laitinen et al., 1997) i.n. K7 Atherosclerosis 
 (Muhlestein et al., 1998) i.n. VR1310 Atherosclerosis 
 (Fong et al., 1999a) i.n. AR-39 Atherosclerosis 
 (Fong et al., 1999b) i.n. VR1310 Atherosclerosis 
 (Tambiah et al., 2001) laparotomy na AAA 
 (Coombes et al., 2002) i.n. na Atherosclerosis 
 (Tambiah and Powell, 2002) laparotomy na AAA 
 (Gieffers et al., 2004b) i.t. CV-6 Infection course 
Pig (Liuba et al., 2003b) i.t. IOL-207 Atherosclerosis 
 (Pislaru et al., 2003) i.c., i.b. AR-39 Atherosclerosis 
Rat (Herrera et al., 2003) i.n. AR-39 Atherosclerosis 
Hamster (Sambri et al., 2004) i.p., i.n. FB/96 Infection course 
 (Finco et al., 2005) i.p. FB/96 Immunology 
Abbreviations used in this table: i.t.=intratracheal; i.n.=intranasal; i.c.=intracoronary; 
i.b.=intrabronchial; na=not assessed; i.p.=intraperitoneal; Cpn=C. pneumoniae;
AAA=abdominal aortic aneurysm. 
1.4 Factors determining the persistence of C. pneumoniae infection in lung 
1.4.1 Pulmonary inflammation 
C. pneumoniae readily infects in vitro and in vivo cells from both the upper and the lower 
respiratory tract (Wong et al., 1992; Yang et al., 1994; Shemer-Avni and Lieberman, 
1995; Alakärppä et al., 1999; Jahn et al., 2000; Meijer et al., 2000; Haralambieva et al., 
2004). Deciliation of ciliated cells also occurs (Yang et al., 1994; Shemer-Avni and Lie-
berman, 1995). Attachment and invasion into epithelial cells activate directly e.g. nuclear 
factor-κβ activation/translocation and secretion of pro-inflammatory cytokines (IL-8), 
interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), expression of leukocyte adhesion 
molecules, and subsequent enhanced polymorphonuclear (PMN) leukocyte transepithelial 
migration (Jahn et al., 2000; Yang et al., 2003). In mice, the expression of histidine de-
carboxylase, which generates histamine from histidine, is increased, especially in bron-
chial epithelial cells, which may have a deleterious role in C. pneumoniae infection 
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(Burian et al., 2003). The surfactant proteins A and D enhance the phagocytosis of C.
pneumoniae (Oberley et al., 2004). In the alveoli, release of surfactant protein A by Type 
II pneumocytes may be inhibited during C. pneumoniae infection (Wissel et al., 2003). 
The presence of inflammatory cells and inflammatory mediators in lungs reflect the 
local defense against invading C. pneumoniae. In mice, histology implies interstitial 
pneumonitis of varying severity during C. pneumoniae infection. The cellular picture 
during infection is of chronic type, i.e. it mainly consists of mononuclear cells, in peri-
bronchial and perivascular infiltrations, although in the first few days PMN leukocytes 
may also infiltrate in large amounts into the bronchioles, alveolar space, and interstitium. 
Lymphoid follicles are also seen. (Kaukoranta-Tolvanen et al., 1993; Yang et al., 1993; 
Yang et al., 1994). In the C. pneumoniae mouse model, primary infection gives partial 
protection against reinfection. The role of various cell types in the overall outcome of 
infection or in the protection against reinfection has been studied, and T cells, both CD8+ 
and CD4+, were found protective (Penttilä et al., 1999; Rottenberg et al., 1999). C.
pneumoniae-specific CD8+ have a T-helper 1 (Th1) type cytokine pattern, which is con-
sidered favorable for clearance, and they are able to lyse C. pneumoniae-infected cells. 
Multiple CD8+ cytolytic antigens/epitopes have been screened from the genome, some of 
which are protective (Saren et al., 2002; Wizel et al., 2002). The Th1 type also predomi-
nates against complete Pmps8, 20, and 21, and both CD8+ and CD4+ are needed for 
maximal responses (Mygind et al., 2004). Natural killer cell cytotoxicity does not seem to 
be necessary for controlling C. pneumoniae infection (Rottenberg et al., 2000). 
The various protective effects of CD4+ cells, CD8+ cells, and macrophages seem to be 
mediated through IFN-γ secretion (Rothfuchs et al., 2004). IFN-γ also participates in the 
induction of e.g. tryptophan deprivation, inducible nitric oxide synthase (iNOS), iron 
deprivation, Th1/Th2 balance, and chemokine and adhesion molecule expression. In 
mouse pulmonary infection, IFN-γ restricts the growth of chlamydiae and histopathologi-
cal changes and strengthens the Th1 type response (Penttilä et al., 1998a; Rottenberg et 
al., 1999; Vuola et al., 2000). Deleterious effects in C. pneumoniae infection and more 
severe disease are suggested to be mediated through delayed IFN-γ transcription and en-
hanced interleukin-4 (IL-4) and IL-10 transcription in lungs (shift from Th1 to Th2) 
(Rottenberg et al., 1999), high nitric oxide responders (Huang et al., 2002), and reduced 
iNOS transcription (Rottenberg et al., 1999). 
1.4.2 Persistence of C. pneumoniae
Importantly, C. pneumoniae is able to resist immune defense and replicates and persists 
within immune cells. In addition to being able to replicate within phagocytes, macro-
phages, and neutrophils, C. pneumoniae replicates within nonphagocytic lymphocytes as 
well (Gaydos et al., 1996; Haranaga et al., 2001; van Zandbergen et al., 2004). Failure to 
clear the infection is due to several factors. The predominance of the Th2 type response 
in chlamydial diseases is usually associated with a failure in clearance (Holland et al., 
1996). Chlamydiae may hamper the presentation of its antigens - chlamydial protease-
like activity factor has been shown to degrade transcription factors and to suppress major 
histocompatibility complex class I and II expression (Zhong et al., 1999; Zhong et al., 
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2000). Inhibition of apoptosis in several cell types, including immune cells, such as blood 
mononuclears and neutrophils (Geng et al., 2000b; Rajalingam et al., 2001; Airenne et al., 
2002; van Zandbergen et al., 2004), may also predispose to chronicity. A certain cell type, 
type II alveolar epithelial cells (surfactant protein-A positive cells), has been found to be 
the host for C. pneumoniae in chronic lung disease (COPD) (Rupp et al., 2004a). 
In vitro, chlamydial persistence is characterized by an altered developmental cycle 
(reviewed in (Beatty et al., 1994b)): development of aberrant forms and interruption in 
the development of infective EB forms. Transcription and translation are also altered in 
persistent chlamydial infection (Mathews et al., 2001; Molestina et al., 2002). In persis-
tent C. pneumoniae infection, the expression of genes needed for DNA replication, repair, 
and chromosome segregation continues, but those encoding proteins for cell division are 
not involved (Byrne et al., 2001). ATP is probably derived from the host cell during per-
sistence (Gerard et al., 2002). Importantly, persistent in vitro chlamydial infection in-
duced by concentrations of IFN-γ not high enough to kill can be reactivated by anti-IFN-γ
treatment or by replacing IFN-γ−containing medium with medium that does not contain 
IFN-γ (Shemer and Sarov, 1985; Beatty et al., 1993b; Mehta et al., 1998) through reor-
ganization of persistent forms to infective EBs (Beatty et al., 1995). In experimental ani-
mals, C. pneumoniae infection can be reactivated with immunosuppressive treatment 
(Malinverni et al., 1995a; Laitinen et al., 1996). Concerning C. pneumoniae in vitro,
spontaneous persistence takes place in blood mononuclear cells and alveolar macro-
phages (Airenne et al., 1999; Haranaga et al., 2003). In addition, persistence of C. pneu-
moniae can be induced by several agents in vitro, including IFN-γ alone or in combina-
tion with TNF-α (Summersgill et al., 1995), tobacco smoke (Wiedeman et al., 2004), and 
several antibiotics (Gieffers et al., 2004a). 
1.4.3 Hsp60 in chlamydial persistence 
In persisting chlamydial infections and associated chronic inflammation,  the 60 kD Heat 
shock protein (Hsp), called chlamydial Hsp60 (cHsp60), is of special interest among the 
chlamydial antigens (Morrison et al., 1989; Toye et al., 1993). Hsps function as chaper-
ones, and both microbial and host cells express large amounts of Hsps during infection. 
Both mammalian and microbial Hsps are able to induce activation of the immune system, 
and microbial Hsps are likely targets of the host immune response, because they may be 
processed along with other antigens and presented to macrophages, and they further con-
tain conserved epitopes enabling interspecies cross-reaction (Young et al., 1988; Young 
and Elliott, 1989; Zügel and Kaufmann, 1999). 
Chlamydiae have three Hsp60 genes (Stephens et al., 1998), and the proteins Hsp60 1-
3 are encoded by the genes groEL1 – 3 (Kalman et al., 1999). At the amino acid level, 
GroEL1 is the most conserved among the chlamydial species (91-98%), while GroEL2 
and GroEL3 are conserved at a lower level (26-37%) (Karunakaran et al., 2003). There is 
a negative regulator protein HrcA, which binds to the CIRCE element found in groEL1
containing groE operon (Wilson and Tan, 2002). Expression of Hsp60 (Hsp60 1) during 
actively replicating C. trachomatis infection in vitro occurs throughout the developmental 
cycle and may correlate with metabolic activity (Shaw et al., 2000). cHsp60 is detectable 
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inside a C. pneumoniae inclusion and in the culture supernatant, and it stimulates innate 
immune cells both in vitro  and in vivo (da Costa et al., 2002; da Costa et al., 2004). During 
persistent IFN-γ−induced C. trachomatis infection, cHsp60 is found at almost normal levels 
compared to the low levels of, e.g., MOMP (Beatty et al., 1993a; Beatty et al., 1995). In C. 
pneumoniae, Hsp60/GroEL protein expression is also increased in persistent IFN-γ-induced 
infection (Molestina et al., 2002), and the Hsp60 expression of C. pneumoniae is similarly 
high in persistent alveolar macrophage infection (Haranaga et al., 2003) and in ex vivo
COPD lung specimens (Rupp et al., 2004a). In persistent C. trachomatis serovar K infec-
tion, different transcription patterns were identified for the three different genes compared 
to active infection, and this pattern correlated with that of synovial tissue samples from C. 
trachomatis reactive arthritis patients (Gerard et al., 2004). 
1.5 Association of atherosclerosis and C. pneumoniae infection 
Although there are reports from as early as the mid-20th century focusing on the associa-
tion of chlamydial (psittacosis and lymphogranuloma venereum) with arterial and cardiac 
diseases (Coutts and Davila, 1945; Sutton et al., 1967), the initial seroepidemiological 
study on the association of C. pneumoniae and atherosclerosis was published in 1988 
(Saikku et al., 1988). Thereafter, other seroepidemiological studies as well as studies on 
the detection of C. pneumoniae in atherosclerotic lesions by electron microscopy, immu-
nohistochemistry, PCR, and culture have been published (Shor et al., 1992; Kuo et al., 
1993; Ramirez, 1996). Animal experiments revealed the development of atherosclerotic 
changes due to infection (Fong et al., 1997; Laitinen et al., 1997). Results from the first 
two small antibiotic prevention studies in humans were positive, but larger studies con-
ducted thereafter have been controversial (Gupta et al., 1997; Gurfinkel et al., 1997; 
Wells et al., 2004; Anderson, 2005). 
Chronic and relapsing C. pneumoniae infections are difficult to diagnose, which ham-
pers association studies (Boman and Hammerschlag, 2002). In addition, studies on the 
effects of microbial and host gene polymorphism on the outcome of infection are just 
emerging. Yet, it is known that C. pneumoniae isolates vary in the copy number of the 
tyrP encoding an aromatic amino acid transporter - respiratory isolates have multiple cop-
ies, and cardiovascular isolates have only one copy of the gene (Gieffers et al., 2003). 
Diversity in omp1 between the respiratory isolates and the coronary isolate has also been 
reported (Molestina et al., 1998). The presence of C. pneumoniae bacteriophage (?Cpn1) 
has been associated with AAA, although ?Cpn1 does not contain any known virulence 
genes (Karunakaran et al., 2002). Certain host gene polymorphisms in the CD14 pro-
moter with enhanced expression have been associated with C. pneumoniae infection 
(Heinemann et al., 1996; Eng et al., 2003) and, further, with chronic C. pneumoniae in-
fection diagnosed by the presence of chlamydial DNA in peripheral blood monocytes of 
coronary artery disease (CAD) patients (Rupp et al., 2004b). In addition, IL-1 polymor-
phism has been linked with CAD in connection with C. pneumoniae infection 
(Momiyama et al., 2001), and C. pneumoniae seropositivity seems to be associated with 
high Lipoprotein(a) levels and certain human leukocyte antigen class II genotypes 
(Dahlen et al., 1995). 
24
1.5.1 Inflammation in atherogenesis 
Atherosclerosis is considered a low-grade chronic inflammatory disease of the arterial 
wall. The hallmark of the disease is lipid accumulation into the blood vessel walls. Lipids 
and inflammatory markers are present in circulating blood (reviewed in (Libby et al., 
2002)). Slightly elevated levels of CRP have been shown to predict subsequent cardio-
vascular events (Libby and Ridker, 2004). The levels of CRP and other acute phase pro-
teins increase to various degrees in several stress conditions, e.g. ongoing infection, in-
flammation, and trauma (Gabay and Kushner, 1999). During C. pneumoniae pneumonia, 
CRP levels are elevated, but remain lower than in, for instance, S. pneumoniae pneumo-
nia or in coinfection by these two microbes (Kauppinen et al., 1996). Overall, the aggre-
gate number of pathogens (pathogen burden) has been associated with the degree of in-
flammation, the extent of atherosclerosis, and the risk for death (Zhu et al., 2000; Zhu et 
al., 2001; Espinola-Klein et al., 2002a; Espinola-Klein et al., 2002b). 
In the development of atherosclerotic lesions, endothelial dysfunction is the initial event, 
which leads to increased adhesion of leukocytes to the vascular wall and to inflammation. 
The earliest atherosclerotic lesion type, the fatty streak, is an inflammatory lesion consisting 
of T lymphocytes (both CD4+ and CD8+) and monocyte-derived macrophages. Foam cells 
are formed from macrophages in the presence of lipids. (Fig. 4) If the inflammatory process 
continues, more complicated lesions evolve, i.e. intermediate lesions, with smooth muscle 
cell migration and proliferation in the inflammation area. In an advanced, complicated le-
sion, the fibrous cap overlies the lipid and necrotic tissue containing core. Such lesions ex-
pand in their shoulder region, where leukocytes adhere (Ross, 1999). For the histological 
identification of different lesion types, American Heart Association has published instruc-
tions for the differentiation of each lesion type (Stary et al., 1994; Stary et al., 1995; Stary, 
2000). The initial fatty streak and the intermediate lesion types I, II, and III are able to re-
gress to normality. Most clinical events occur when type VI lesions and also type IV and V 
lesions are present. These lesion types are non-regressive. 
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Fig. 4. Fatty streak formation in atherosclerosis development (Ross, 1999). (With permission, 
Copyright ? 2005 Massachusetts Medical Society).  
1.5.2 Mouse models for C. pneumoniae and atherosclerosis 
Mice primarily have a non-atherogenic lipid profile, as most of their cholesterol is carried 
in high-density lipoprotein (HDL) particles. They are thus quite resistant to atherosclero-
sis, but disturbances of normal cholesterol metabolism lead to atherosclerotic changes. 
Atherosclerosis experiments have conventionally been done in wild-type mice by modi-
fying the diet to obtain high fat and high cholesterol concentrations in the circulation. 
Another approach is genetical alterations of the mouse to have excess cholesterol in the 
circulation and altered lipid metabolism. ApoE and LDL receptor are important mole-
cules in the clearance of harmful low-density lipoprotein (LDL) cholesterol (Breslow, 
1993).
In C. pneumoniae mouse models, both genetic and diet-induced approaches have been 
used. Both extension and progression of lesions have been reported. To obtain chronic 
infection in mice, repeated exposures with C. pneumoniae are used (Grayston et al., 
1985; Beatty et al., 1994a). The impact of C. pneumoniae infections on atherosclerotic 
lesions in ApoE-deficient mice has varied, but in other genetically modified mouse 
strains, studies have shown uniformly that repeated infections have increased either the 
lesion area or the severity of lesions (Table 3). Even advanced lesions develop in these 
genetically modified mouse strains. 
26
Table 3. Mouse models for C. pneumoniae (as a sole pathogen) and atherosclerosis using 
genetically modified mouse strains. 
Deficiency Infection Diet Impact Reference 
 No Age* Age** Type on lesions  
ApoE 3 8 - chow Increase in area (Moazed et al., 1999) 
ApoE 1-3 na - chow Endoth. dysfunction (Liuba et al., 2000) 
ApoE 3, 4 
3, 4 
8
8
-
na
chow 
high fat 
No effect 
No effect 
(Aalto-Setälä et al., 
2001)
ApoE 2 6 - chow Increase in area*** (Burnett et al., 2001) 
ApoE 1, 2 6-8 - chow No effect (Caligiuri et al., 2001) 
ApoE 2 
2
10 
12 
-
-
chow 
chow 
No effect 
Increase in area 
(Rothstein et al., 
2001)
ApoE 3 7 - chow No effect (Liuba et al., 2003a) 
ApoE3**** 2 9 5 high fat Increase in severity (Ezzahiri et al., 2002) 
LDLR 9 
9
4-5
4-5
-
na
chow 
2% chol. 
No effect 
Increase in area and 
severity 
(Hu et al., 1999) 
LDLR 12 4-6 na 2% chol. Increase in area (Liu et al., 2000) 
LDLR 4-6 4-6 2-4 2% chol Increase in area (Sharma et al., 2004) 
ApoE+LDLR 2, 6 16 - chow Reduce fibrous cap (Ezzahiri et al., 2003) 
eNOS 
iNOS 
3
3
8
8
8
8
high fat 
high fat 
No effect 
Increase in area 
(Chesebro et al., 
2003)
* age of the mouse at the first C. pneumoniae challenge, in weeks 
** if a modified diet was used, the age of the mouse when the diet was initiated, in weeks 
*** in males only 
**** transgenic mouse strain, which has ApoE3-Leiden insertion 
Abbreviations used in this table: ApoE=Apolipoprotein E; LDLR=LDL receptor; 
eNOS=endothelial nitric oxide synthase; iNOS=inducible nitric oxide synthase; na=not 
assessed; chow=maintenance regular diet; chol=cholesterol. 
Among several wild-type strains, the C57BL/6J strain has been shown to be most prone 
to lesion development when on a high-fat diet (Paigen et al., 1985), although only initial 
type I and fatty streak type II lesions are seen. In C. pneumoniae models, the high-fat diet 
must be initiated either before the first C. pneumoniae inoculation or simultaneously to it 
to obtain the atherogenic effect of C. pneumoniae (Table 4). If a wild-type C57BL/6J 
mouse is repeatedly infected with C. pneumoniae and fed a non-modified diet, only in-
flammatory changes in the aortic wall are induced. 
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Table 4. Mouse models for C. pneumoniae (as a sole pathogen) and atherosclerosis using 
wild-type mouse strains. 
Mouse Infection Diet Impact Reference 
strain No Age* Age** Type on lesions***  
C57BL/6J 1, 3 8 - chow Inflammation (Blessing et al., 2000) 
C57BL/6J 3 
3
8
8
-
8
chow 
high fat 
No effect 
Increase in area 
(Blessing et al., 2001) 
C57BL/6J 1 6-8 - chow No effect (Caligiuri et al., 2001) 
C57BL/6J 3 8 13, 15 high fat No effect (Blessing et al., 2002a) 
C57BL/6J 3 8 8 high fat Increase in area (Chesebro et al., 2003) 
C57BL/6J 3 8 6 0.2% chol. Increase in area (Erkkilä et al., 2004) 
BALB/c*** 1-3 6-8 - chow Inflammation (Burian et al., 2001a) 
* age of the mouse at the first C. pneumoniae challenge, in weeks 
** if a modified diet was used, the age of the mouse when the diet was initiated, in 
weeks 
*** the mice were γ-irradiated. 
Abbreviations used in this table: chow=maintenance regular diet; chol=cholesterol. 
1.5.3 Role of C. pneumoniae in lesion development 
C. pneumoniae infection may contribute to lesion development in several stages (re-
viewed in (Mahony and Coombes, 2001)). Being a respiratory pathogen, C. pneumoniae
may be directly shed into the bloodstream from the lungs or carried within infected 
monocytes/macrophages through bronchus-associated lymphatic tissue and lymphatics 
into the circulation (Yang et al., 1995; Moazed et al., 1998; Gieffers et al., 2004b). C.
pneumoniae–infected monocytes adhere through activation of their integrin adhesion 
receptor system to noninfected arterial endothelial cells (Kalayoglu et al., 2001; May et 
al., 2003) and transfer C. pneumoniae to endothelial cells (Lin et al., 2000) and further to 
smooth muscle cells beneath the endothelial cell layer (Rupp et al., 2005), in which C. 
pneumoniae is able to multiply (Kaukoranta-Tolvanen et al., 1994; Godzik et al., 1995; 
Gaydos et al., 1996). In endothelial cells, C. pneumoniae infection induces inflammation 
(Kaukoranta-Tolvanen et al., 1996; Molestina et al., 1998; Krüll et al., 1999; Molestina et 
al., 1999; Coombes and Mahony, 2001). Cytosolic Nod proteins participate in the recog-
nition and activation of inflammation due to intracellular C. pneumoniae (Opitz et al., 
2005). TLR2-dependent activation in endothelial cells occurred only by extracellular C. 
pneumoniae (Opitz et al., 2005). Also, TLR4 has been reported to participate in the rec-
ognition of C. pneumoniae (Prebeck et al., 2001). cHsp60 and LPS may provide a source 
for a continuous inflammatory stimulus. Chlamydial LPS gives only a weak inflamma-
tory stimulus, which probably serves to allow persistence. Chlamydial LPS-containing 
immune complexes are present in acute myocardial infarction patients (Leinonen et al., 
1990). cHsp60 can be found in human atheroma, and it induces TNF-α expression (Kol et 
al., 1998) and activates vascular adhesion molecules as well as the production of proin-
flammatory IL-6 in vascular cells: endothelial cells, smooth muscle cells, and macro-
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phages (Kol et al., 1999). cHsp60-responding T cells are found in the lesion (Curry et al., 
2000; Mosorin et al., 2000). 
Along with inflammatory activation, C. pneumoniae is able to induce the formation of 
foam cells, which is the initial step in lipid lesion development (Kalayoglu and Byrne, 
1998). Vice versa, macrophage foam cells can be infected with C. pneumoniae (Blessing 
et al., 2002b). In addition, C. pneumoniae and cHsp60, but not LPS, alone were able to 
induce cellular oxidation of LDL in the supernatant (Kalayoglu et al., 1999). 
Smooth muscle cell proliferation is an important step in lesion progression and fibrous 
cap formation, and C. pneumoniae and cHsp60 are able to trigger it (Sasu et al., 2001; 
Hirono et al., 2003). Although these steps lead to narrowing of the artery, they simultane-
ously add stability to the atherosclerotic lesion. However, C. pneumoniae infection as 
well as cHsp60 and human Hsp60 (hHsp60) may also induce events that lead to unstabil-
ity and fibrous cap degradation, by expression and secretion of matrix metalloproteinase, 
which contributes to tissue damage by proteolytic activity (Kol et al., 1998; Vehmaan-
Kreula et al., 2001). 
1.5.4 Hsp60 autoimmunity 
1.5.4.1 Hsp60 autoimmunity in atherogenesis 
The protective stress response may ultimately lead to the development of autoimmune 
response against the conserved epitopes of self-stress proteins. It may develop as a con-
sequence of repeated microbial exposure and is suggested to be beneficial for the removal 
of defective host cells, the maintenance of a general level of protection, the first-line de-
fence in infection, and the elimination of stressed cells infected by intracellular bacteria 
(reviewed by (Young and Elliott, 1989)). Autoimmunity to Hsps may, however, contrib-
ute to the pathogenesis of several chronic inflammatory diseases (Zügel and Kaufmann, 
1999). Indeed, Hsp60 autoimmunity has been suggested to participate in atherogenesis 
(Wick et al., 1995). In humans, mycobacterial Hsp65 (mbHsp65) antibodies, which cross-
react with hHsp60, were increased in patients with carotid atherosclerosis (Xu et al., 
1993b; Xu et al., 1993c). Soluble Hsp60 levels in serum also strongly correlate with 
atherosclerosis as well as with markers of inflammation and infection (Xu et al., 2000). 
Parenteral mbHsp65 immunization of normocholesterolemic rabbits leads to atheroscle-
rotic lesion development (Xu et al., 1992), and in combination with a cholesterol-rich 
diet, advanced lesions develop (Xu et al., 1996). MbHsp65-reactive antibodies and T 
cells are found in the lesions of mbHsp65-immunized animals (Xu et al., 1993a). Interest-
ingly, mucosal administration of mbHsp65 in high-cholesterol/fat-fed LDL receptor-
deficient mice decreases atherosclerotic plaques (Harats et al., 2002; Maron et al., 2002). 
29
1.5.4.2 Chlamydial infection and Hsp60 autoimmunity in atherogenesis 
In cHsp60, B-cell and T-cell epitopes conserved and cross-reactive with hHsp60 have 
been detected (Yi et al., 1993; Witkin et al., 1994). Self-Hsp60-reactive antibodies and T 
cells are induced in mice simultaneously immunized with cHsp60 and mouse Hsp60 
(mHsp60), but not if either agent is given alone (Yi et al., 1997). In humans, cross-
reactive Hsp60 antibodies exist (Domeika et al., 1998). In atherosclerosis, mbHsp65 im-
munity correlates with C. pneumoniae and Helicobacter pylori infections (Mayr et al., 
2000), and high levels of immunoglobulin G (IgG) antibodies to both cHsp60 and 
hHsp60 are independent and combined risk factors for atherosclerosis (Burian et al., 
2001b; Mahdi et al., 2002). In addition, cHsp60 IgG antibodies correlate with the detec-
tion of C. pneumoniae in human atheroma (Fong et al., 2002). For coronary risk, elevated 
levels of hHsp60 IgA, C. pneumoniae IgA and CRP are powerful predictors when present 
together, and especially when persistently elevated (Huittinen et al., 2002; Huittinen et 
al., 2003). 
The mechanisms in atherogenic Hsp60 autoimmunity are proposed to act through re-
activity with Hsp60 expressed on the surface of stressed endothelial cells and endothelial 
cytotoxicity (Xu et al., 1994; Schett et al., 1995) Hsp60 expression is increased in endo-
thelial cells in atherosclerotic lesions in humans and in rabbits, but not in disease-free 
rabbit vessels (Kleindienst et al., 1993; Xu et al., 1993a). In experimental animals, the 
expression of Hsps in aortic endothelial cells is enhanced in stress condition, such as cho-
lesterol-rich diet (Xu et al., 1993a), hypercholesterolemia (expression correlated with the 
development of lesions) (Kanwar et al., 2001), exposure to LPS (Seitz et al., 1996), fluc-
tuation in blood flow (Hochleitner et al., 2000), or in vitro in monocytic cells by oxidized 
LDL (Frostegard et al., 1996). C. pneumoniae infection in endothelial cells also uppregu-
lates Hsp60 expression (Shi and Tokunaga, 2004). Hsp65/60 antibodies that cross-react 
with hHsp60 and cHsp60, as well as E. coli GroEL, are able to mediate endothelial cyto-
toxicity (Mayr et al., 1999). 
1.5.5 Statins and their antimicrobial effects 
Statins are lipid-lowering drugs that are widely used to prevent cardiovascular diseases 
(reviewed in (Maron et al., 2000)). They competitively inhibit the 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase in the mevalonate pathway of isopre-
noid biosynthesis, which is also the rate-limiting enzyme in the cholesterol biosynthesis 
pathway. This inhibition ultimately leads to decreased LDL cholesterol levels in serum 
(Endo et al., 1977; Corsini et al., 1995). In addition to their lipid-lowering effect on circu-
lating and lesional lipids, statins have other effects also considered protective against 
atherosclerosis and its complications, e.g. immunomodulation, reduction of cellular activ-
ition and proliferation, and improvement of endothelial function and vasomotion (re-
viewed in (Vaughan et al., 1996)). It has been shown that pravastatin also decreases coro-
nary events in patients with average cholesterol levels (Sacks et al., 1996) and with 
slightly elevated CRP levels, and further, that they decrease elevated CRP levels (Ridker 
et al., 1999; Strandberg et al., 1999). Several immunomodulatory effects have been re-
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ported (Kwak et al., 2000; Loike et al., 2004; Schonbeck and Libby, 2004), and both in-
nate and acquired types of immunity are affected. In vivo, the influx of different leuko-
cytes, PMN leukocytes, eosinophils, macrophages, and lymphocytes due to inflammatory 
stimuli is inhibited, (Diomede et al., 2001; Sparrow et al., 2001; McKay et al., 2004; Wil-
liams et al., 2004; Yeh and Huang, 2004). Different statins may, however, have different 
immunomodulatory effects (Kiener et al., 2001). 
Through inhibition of HMG-CoA reductase in the mevalonate pathway, statins also 
inhibit isoprenoid biosynthesis in eucaryotes and also in some bacteria (Hedl et al., 2002). 
C. pneumoniae does not have the HMG-CoA reductase enzyme, but in vitro studies have 
shown that cerivastatin tends to reduce infection rates in macrophages, and the secretion 
of monocyte chemoattractant protein-1 (MCP-1) and IL-8 decreased both in macrophages 
and endothelial cells (Kothe et al., 2000). Dechend et al. have shown that cerivastatin 
reduces C. pneumoniae infection of smooth muscle cells via infected human macro-
phages and blocks cell membrane-associated RhoA and Rac1 through inhibition of 
prenylation, reactive oxygen production, and RANTES and MCP-1 (Dechend et al., 
2003). Statins also reduce the intracellular growth of Salmonella enterica serovar Typhi-
murium in vitro and in vivo in mouse (Catron et al., 2004) and inhibit in vitro the growth 
of two viruses, cytomegalovirus (Potena et al., 2004) and HIV-1. Inhibition of HIV-1 also 
occurred in vivo in infected patients (del Real et al., 2004). In a sepsis mouse model 
(gram-negative rods, gram-positive cocci), simvastatin treatment improved survival and 
reversed increased monocyte adhesion to endothelium (Merx et al., 2004), and in a LPS-
induced sepsis model, cerivastatin improved survival and reduced the levels of inflamma-
tory mediators (Ando et al., 2000). In humans, too, statin treatment has been shown to 
reduce mortality in bacteremic patients (Liappis et al., 2001) and to reduce the rate of 
severe sepsis (Almog et al., 2004). 
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2 Aims of the study 
The present project was carried out using mouse models for C. pneumoniae infection. 
The specific aims were to analyze: 
1. Technical aspects of the mouse model, i.e. the impact of the anesthetic agent on 
inoculating the mice and the presence of host cell remnants in the inoculum 
2. Pulmonary infection and inflammation caused by different C. pneumoniae iso-
lates administered via different inoculation routes and during cholesterol feeding 
3. Development of cHsp60 and mHsp60 antibody responses and development of 
atherosclerotic lesions 
4. Effects of simvastatin treatment on immune and inflammatory responses and C. 
pneumoniae growth 
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3 Materials and methods 
3.1 Mouse model 
3.1.1 Mice and diets 
The Animal Care and Use Committee of National Public Health Institute, Helsinki, ap-
proved all procedures involving experimental animals in this project. The following 
mouse strains were used in the experiments: female inbred C57BL/6JBom mice (M&B 
A/S, Ry, Denmark) (I, III) and female outbred NIH/S mice (National Public Health Insti-
tute, Kuopio, Finland) (I, II, IV). The mice were specifically pathogen-free, and they 
were maintained under pathogen-free conditions and handled using Biosafety level-II 
precautions. The temperature, relative humidity, number of air changes, and photoperiod 
were automatically controlled in the animal facilities. 
The mice were allowed an autoclaved or irradiated regular chow diet (Altromin 1324, 
Chr. Petersen A/S, Ringsted, Denmark) and water ad libitum. In study III, a group of mice 
were fed an autoclaved regular chow diet with 0.2% cholesterol supplement. In study IV, 
a group of mice were fed a high-fat diet consisting of 21% total fat, 0.2% cholesterol, and 
19.5% casein (Harlan Teklad, Horst, The Netherlands). 
3.1.2 C. pneumoniae challenge 
The mice were given an infectious challenge i.n. under light carbon dioxide (CO2) or meth-
oxyflurane (Metofane; Pitman-Moore, Mundelein, IL, USA) anesthesia. Control mice were 
given similarly sucrose-phosphate-glutamate (SPG) solution. Two different C. pneumoniae
isolates, which are both throat swab isolates, Kajaani 6 (K6) (I, II) or Kajaani 7 (K7) (I, III, 
IV), from an epidemic in Finnish military conscripts (Ekman et al., 1993) were used to 
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challenge the mice. Both isolates have been propagated in HL (a human epithelial cell line) 
cells and stored in SPG solution at -70oC (National Public Health Institute, strain collec-
tion). The infectious challenge was a crude chlamydial preparation consisting of C. pneu-
moniae particles, mainly EBs, and HL host cell remnants. The infectious dose per mouse, 
which was quantified directly after the challenge, varied between 1.8x105 and 2.0x106 in-
clusion-forming units (IFU) in different experiments. 
In one experiment, a cellular preparation consisting of HL host cell remnants was 
given to a control group of NIH/S mice and also before or after the C. pneumoniae chal-
lenge (II). In study III, C57BL/6J mice were fed either a regular chow diet or a regular 
chow diet with 0.2% cholesterol supplementation and repeatedly infected. The 1st reinfec-
tion was given 7 weeks after the primary infection, and the 2nd reinfection was given 11 
weeks after the primary infection, i.e. 4 weeks after the 1st reinfection (III). A separate 
experiment was also performed where a group of C57BL/6J mice were infected i.n. and 
another group intragastrically (i.g.). The i.g. inoculation was given under Hypnorm seda-
tion. 
3.1.3 Other treatments (IV) 
In study IV, a group of NIH/S mice on a regular chow diet and a group on a high-fat diet 
were treated with simvastatin. Simvastatin (L-644, a gift from Merck) was dissolved in 1 
% dimethylsulfoxide (1 % DMSO), and the selected daily dose (0.5 mg/kg) was given as 
i.p. injections (100 μl) for 24 consecutive days. Control groups of NIH/S mice were 
treated with the same volume of vehicle. 
3.2 Detection of C. pneumoniae
3.2.1 Chlamydial culture (I, II, III, IV) 
For the detection of infective chlamydia in different tissues of the mice, the tissue sam-
ples were mechanically homogenized (Stomacher blender) in SPG, and the supernatant of 
the tissue homogenate was inoculated in several volumes into either HL or Vero cells 
(Green monkey kidney cell line) grown in 24-well plates. After pipetting the samples into 
the wells, the plates were centrifuged at 550 x g for 1 h, and the the media were replaced 
with media containing 0.5 μg/ml cycloheximide and incubated for 72 hours. Cells were 
fixed with methanol and stained with fluorescein isothiocyanate-conjugated chlamydia 
LPS-specific antibodies (Pathfinder Chlamydia Confirmation System, Kallestad Diagnos-
tics, Chaska, MN). 
34
3.2.2 Detection of C. pneumoniae DNA by PCR (II, III, IV) 
For the detection of C. pneumoniae DNA from samples of mouse tissue, DNA was ex-
tracted using the QIAamp Tissue Kit (Qiagen GmbH) by following the manufacturer’s 
instructions. One to 10 μl of DNA extract was used for the PCR reaction. Three different 
PCR protocols were used in this project. In the first PCR protocol (II), the PCR reaction 
was performed using the C. pneumoniae 16S rRNA gene-specific primers CpnA and 
CpnB, which result in a 463 bp product (Gaydos et al., 1992). The reaction was done in a 
25 μl mixture with AmpliTaq GOLD polymerase (PE Biosystems), and the cycle number 
was 40. The PCR products were visualized in a 2% agarose gel electrophoresis. The sec-
ond PCR protocol (III), hot-start PCR, was performed using C. pneumoniae omp1 -
specific biotinylated primers (Institute of Biotechnology, Helsinki, Finland) with Ampli-
Taq polymerase (Promega) and AmpliWax Gem 50 bed (PE Biosystems) in a total reac-
tion volume of 50 μl. The cycle number was 50. The presence of a specific PCR product 
was confirmed by measuring time-resolved fluorescence in liquid hybridization with Eu-
labeled SJ1 probes (Institute of Biotechnology) in streptavidin-coated microplates (Wal-
lac). The third (IV) and fourth (i.g. infection experiment) PCR protocols were real-time 
quantitative protocols for Light Cycler machine (Roche), using pmp4 (Mygind et al., 
2001) and 16S rRNA (Gaydos et al., 1992) -specific primers and a hybridization probe in 
a total reaction volume of 25 μl (Reischl et al., 2003). The number of cycles was 50. 
3.3 Inflammation
3.3.1 Pulmonary inflammation (II, III, IV) 
Histopathological analysis was performed on lung samples. The tissue samples were 
fixed using phosphate-buffered formaldehyde and embedded in paraffin. Sections of 4 
μm in thickness were cut from the paraffin blocks using a microtome, and the sections 
were stained with hematoxylin and eosin. The degree of pulmonary inflammation was 
assessed from the mononuclear and polymorphonuclear leukocytes present in the stained 
sections. Grading depended on the number of cells and the area affected. In the mild 
forms, the inflammatory cell infiltrates were limited to the focal areas or occurred in 
small scattered foci, while in the severe cases, large tissue areas were affected. 
3.3.2 Circulating inflammatory markers (IV) 
Serum IL-10 levels were measured using the Quantikine® M mouse IL-10 immunoassay 
kit according to the manufacturer’s instructions (i.g. experiment, R&D Systems). Serum 
amyloid A (SAA) concentrations were measured using a commercial EIA method (IV, 
BioSource International, Camarillo, CA, USA), and serum LBP concentrations were 
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measured from pooled (n=6) mouse sera (HyCult Biotechnology b.v., Uden, The Nether-
lands).
3.4 C. pneumoniae-specific and autoimmune responses (II, III, IV) 
The sera of mice were tested for C. pneumoniae-specific IgG antibodies using enzyme im-
munoassay (EIA). Commercial plates coated with whole C. pneumoniae EBs were used 
(AniLabsystems, Helsinki, Finland) in accordance with the manufacturer’s instructions. 
Mouse sera were tested in 1:100 dilution, and for the detection of bound IgG antibodies, 
alkaline phosphatase-conjugated rabbit anti-mouse IgG (Sigma Chemical Co., St. Louis, 
MO, USA) diluted 1:3000 with PBS containing 10% fetal bovine serum was used. 
From the lungs, using a supernatant of lung tissue homogenate, C. pneumoniae-specific 
IgA antibodies were measured using EIA and commercial plates coated with whole C.
pneumoniae EBs. The supernatant was diluted 1:5, and for the detection of IgA antibodies, 
alkaline phosphatase-conjugated rabbit anti-mouse IgA (Sigma Chemical Co., St. Louis, 
MO, USA) diluted 1:1000 with PBS containing 10% fetal bovine serum was used. 
C. pneumoniae Hsp60-specific IgG antibodies were measured. In EIA, recombinant C. 
pneumoniae Hsp60 protein produced in Bacillus subtilis was used as an antigen 
((Airaksinen et al., 2003), kindly provided by professor Matti Sarvas, National Public 
Health Institute, Helsinki, Finland). The serum samples were diluted 1:1000 and bound 
antibodies were detected using alkaline phosphatase-conjugated anti-mouse immu-
noglobulin diluted in PBS-Tween (Sigma). 
Serum IgG autoantibodies against mHsp60 were measured by EIA using recombinant 
mHsp60 protein as an antigen (StressGen Biotechnologies Corp, Canada). The serum 
samples were diluted 1:10, and bound antibodies were detected using alkaline phos-
phatase-conjugated anti-mouse immunoglobulin (Sigma). 
3.5 Quantification of atherosclerotic lesions and serum lipids (III, IV) 
A method of lesion quantification described by Paigen et al and computer-assisted mor-
phometric measurement were used to quantitate lipid lesions (Paigen et al., 1987). The 
upper part of the heart was fixed in 10% phosphate-buffered formalin and embedded se-
quentially in 5%, 10%, and 25% gelatin. The sections were cut in a plane parallel to the 
atria. Every second of the consecutive 12-14 μm frozen sections was stained with Oil-
Red-O lipid stain, and lipids were counterstained with hematoxylin and Light green. 
True-color digital images were captured with a ColorView 12 video camera (resolution 
1300 x 1300) attached to an Olympus BX-50-F3 light microscope with 20x or 40x objec-
tives. Every third stained section was analyzed for Oil-Red-O stainings using the analy-
SIS software (Soft Imaging System, GmbH). The number of sections (n=4) taken for sta-
tistical analyses was chosen according to the lesions that extended most widely along the 
ascending aorta. The data are expressed as a geometric mean of the Oil-Red-O-stained 
lesion areas with a 95 % confidence interval. 
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Serum total cholesterol and triglycerides were measured with fully enzymatic methods 
(Roche Diagnostics, Basel, Switzerland and Wako Chemicals GmbH, Nuess, Germany). 
3.6 Statistics 
To determine the statistical differences, non-parametric Mann-Whitney U-test, ?2 test, or 
2-sided Fisher's Exact Test was used. P-values of <0.05 were considered statistically sig-
nificant.
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4 Results 
4.1 Technical considerations of C. pneumoniae mouse model 
4.1.1 Effect of anesthetic agent (I) 
Originally, in this mouse model, the mice have been immobilized with CO2 for effective 
delivery of intranasal inoculation. In the present study, methoxyflurane, which is used in 
short- and long-term surgical anesthesia (Danneman and Mandrell, 1997), was compared 
to CO2. C57BL/6J mice were inoculated i.n. with K6 isolate. In the C57BL/6J mice in-
oculated i.n. under methoxyflurane anesthesia, chlamydial culture findings in the lungs 
showed more consistent infection at the days 6 and 12 postinfection (p.i.) than in the mice 
that had been infected under CO2 (I, Table 1). 
4.1.2 Effect of host cell debris in challenge inoculum (II) 
For inoculation of mice with infective C. pneumoniae, a crude preparation, which also 
contained host cell components, was used instead of highly purified EB preparations. 
Possible inflammatory or immune responses against host cell components, such as Hsps, 
were recorded. The results show that only some mild lymphocyte infiltrations were seen 
in the lungs, and no serum IgG response against C. pneumoniae or mHsp60s developed 
(II, Table 1). 
When the mock-inoculated mice were infected 30 days later with K6, the course of in-
fection resembled primary infection, and the chlamydial titres in the lungs were lower 
(day 3 p.i., median 0.7 IFU/sample log10) compared to the lungs of mice which had re-
ceived two K6 infections (day 3 p.i., median 1.5 IFU/sample log10) (II, Table 1). PCR 
positivity correlated with the culture findings in each group. The inflammatory reaction in 
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the lungs, however, was milder compared to the primary infection without mock pre-
treatment and milder than in normal C. pneumoniae reinfection, where the cellular in-
flammatory response in the lungs is fast and strong. (II, Table 1, Fig. 1). In each study 
group, the inflammation began to subside at day 28-30 at the latest. C. pneumoniae
Hsp60 IgG levels rose, as did IgG antibodies against the whole EBs. No mHsp60 IgG 
antibodies were detected. 
A group of mice were primarily infected with C. pneumoniae, and the culture-negative 
mice were inoculated 30 days later with a host cell preparation. After the host cell inocu-
lum, reactivation of infection was detected by culture (II, Table 1). C. pneumoniae PCR 
from lung tissue was also positive, and the lung inflammation was enhanced compared to 
the primary mock inoculation or the mock/mock rechallenge, but was milder than after a 
C. pneumoniae reinfection (II, Table 1). In addition to showing IgG antibodies against 
whole C. pneumoniae EBs and C. pneumoniae Hsp60, some of these mice also developed 
elevated mHsp60 IgG levels (II, Fig. 2). 
4.2 Pulmonary infection and inflammation 
4.2.1 Comparison of the rates of growth of two different C. pneumoniae
Kajaani isolates (I) 
Both of the Kajaani isolates used in the present studies, K6 and K7, are consecutive 
throat swab isolates that have been propagated in HL cells. The K6 isolate has been used 
in mouse and K7 in rabbit studies. The two isolates were now compared in parallel, and 
slightly different infection courses were demonstrated by chlamydial cultures from the 
lungs of NIH/S mice after i.n. infection: inoculation with the K7 isolate led to higher 
chlamydial titers at the early stage than inoculation with the K6 isolate, while opposite 
results were obtained at later time points (I, Table 2). 
4.2.2 Development of pulmonary infection and inflammatory cell 
infiltrations after different challenging routes 
The C57BL/6J mice were infected either i.n. or i.g. After i.n. infection, chlamydia could 
be cultured in large amounts from the lungs, and PCR positivity was also high. The in-
flammation in the lungs, which was seen as patchy mononuclear cell infiltrations around 
the bronchi and veins, was severe and continued till the end of the follow-up. On the con-
trary, after i.g. infection, infective chlamydiae were not cultured from any of the tissues, 
including lungs, liver, and rectal swab, but PCR was positive in a few lung and liver sam-
ples (Table 5). In addition, mild lymphocyte infiltrations were detected in the lungs 
(bronchointerstitial pneumonia) at day 9 p.i., and they increased steadily up to day 34 p.i. 
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(Fig. 5). In addition, in both groups of mice, IL-10 levels in serum were slightly elevated 
at the early time points, and in i.g.-infected mice, a second peak occurred after the lym-
phocyte infiltrations at day 14 p.i.. C. pneumoniae IgG antibodies in serum developed 
(OD>0.10) after i.n. infection at day 9 p.i., and in i.g.-infected mice at day 24 p.i. In the 
lungs, C. pneumoniae IgA antibodies were present after i.n. infection, but not after i.g. 
infection. 
Table 5. Incidence rates (pos./studied) of C. pneumoniae PCR-positive lung and liver 
samples of. primarily i.n. and i.g infected C57BL/6JBom mice at different time points. 
Days postinfection Lung Liver 
 i.n. i.g. i.n. i.g. 
3 6/7 0/7 7/7 2/7 
6 5/7 1/7 5/7 0/7 
9 5/7 0/7 4/7 0/7 
14 3/7 1/7 3/7 1/7 
24 6/7 3/7 2/7 0/7 
34 5/7 1/3 0/7 1/7 
Abbreviations used in this table: i.n.=intranasal; i.g.=intragastric. 
A                  B 
Fig. 5. Hematoxylin and eosin stained lung section from A) a control mouse showing normal 
histopathology of C57BL/6J mouse lung, and B) from an i.g. infected mouse showing mono-
nuclear cell/lymphocyte infiltrates. 
4.2.3 Effect of cholesterol feeding on chronic C. pneumoniae
pulmonary infection (III) 
C57BL/6J mice, which were fed either a regular chow diet or a regular chow diet with 
0.2% cholesterol supplementation, were repeatedly infected with K7. C. pneumoniae
DNA could be detected by PCR at each time point, and the rate varied between the differ-
ent diet groups (III, Fig. 6). After the first reinfection, the rate tended to be higher in the 
mice on a cholesterol-enriched diet than in those fed a regular diet, but after the second 
reinfection, DNA positivity was slightly lower in the mice on a cholesterol-enriched diet 
compared to those fed a regular diet. In the other tissues studied, i.e. hearts, aortic arches, 
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and abdominal aortas, C. pneumoniae DNA was detected intermittently, and in all, the 
DNA positivity was slightly higher in the group of mice fed a cholesterol-enriched diet 
than in the regular diet group. 
In the lungs of repeatedly infected C57BL/6J mice, C. pneumoniae induced typical in-
flammatory changes, i.e. infiltrates of mononuclear cells mainly around the bronchi and 
veins (III, Fig. 4). These inflammatory cell infiltrates persisted up to the last time point 
studied, i.e. 12 weeks after the second reinfection. The cholesterol-enriched diet slightly 
exaggerated the inflammation at the time points after the first reinfection and up to 8 
weeks after the second reinfection (III, Fig. 5). 
4.3 Development of Hsp60 responses and atherosclerotic lesions 
4.3.1 Chlamydial and mHsp60 responses (II, III) 
When NIH/S mice were primary infected with K6 and reinfected 30 days later, the serum 
IgG antibody levels against C. pneumoniae Hsp60 started to rise at day 10 p.i. The levels 
further rose after the reinfection. The C. pneumoniae Hsp60 IgG levels correlated with 
the respective IgG antibody levels against whole C. pneumoniae EBs (r=0.9)(Fig. 6). 
Fig. 6. C. pneumoniae IgG and C. pneumoniae Hsp60 IgG levels. NIH/S mice were primary 
infected and reinfected 30 days later. Different serum dilutions were used (for details, see 
chapter 3.4). 
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In the reinfected NIH/S mice, highly elevated levels (OD 405nm > 0.5) of mHsp60 
IgG antibodies were also present in some individuals (II, Fig. 2). Most of the mice with 
elevated levels also had high C. pneumoniae Hsp60 antibodies present in serum. How-
ever, not all mice with high C. pneumoniae Hsp60 IgG levels had mHsp60 IgG antibod-
ies in their serum. mHsp60 IgG was also found in the repeatedly infected C57BL/6J mice 
that were fed a regular chow diet or a regular chow diet with 0.2% cholesterol supple-
mentation (III, Fig. 2). These IgG autoantibody levels were significantly increased in 
reinfected mice, and a faster increase was detected in the mice fed a cholesterol-enriched 
diet compared to those fed a regular diet. The cholesterol-enriched diet even alone in-
creased the levels transiently. 
4.3.2 Aortic lesions and serum lipids (III) 
Foam cell lesions of two different types were detected in the aortic valve cross-sections 
from repeatedly infected (K7) C57BL/6J mice. One type was present exclusively in the 
media layers in the arterial walls between valve cusps and was not enhanced by C. pneu-
moniae. Another lesion type predominated in the subendothelium at valve cusps and re-
sembled individual and aggregated foam cells in the intima layer (III, Fig. 3). These foam 
cell lesions were significantly increased by the repeated C. pneumoniae infections com-
pared to SPG inoculations of the mice on a cholesterol-enriched diet; 116 ?m2 (95% CI 
32-416 ?m2) versus 7 ?m2 (95% CI 1-62 ?m2), P=0.022, respectively.  Only occasional 
foam cells were detected in the mice on a regular diet independently of the C. pneumo-
niae infection, 2 ?m2 (95% CI 1-5 ?m2) in both groups. 
The cholesterol-enriched diet with 0.2% cholesterol supplementation did not affect the 
serum lipid levels, triglycerides, or total cholesterol. Nor were there differences in these 
circulatory lipid levels due to C. pneumoniae infections. 
4.4 Effect of simvastatin 
4.4.1 Effect of simvastatin treatment on the growth of C. pneumoniae in
mouse lungs (IV) 
In the simvastatin-treated NIH/S mice, infective chlamydiae were detected in decreased 
amounts compared to the vehicle-treated mice. These reductions (55-82%) were seen at 
the early stages of chlamydial infection (days 3 and 6 p.i., respectively) both in the mice 
fed a regular diet and in those fed with a high-fat diet (Fig. 7 and IV, Fig 2). At later time 
points, no marked differences in the counts of viable chlamydiae due to simvastatin 
treatment could be detected. By quantitative PCR, the amount of C. pneumoniae DNA 
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also decreased at same time points and to the same degree as the amount of infective 
chlamydiae (Fig. 7). 
Fig. 7. Chlamydia culture (IFU) and C. pneumoniae PCR (genome equivalent) results from 
the lung tissue of mice fed a) a regular chow diet, or b) a high-fat diet. The results are shown 
as median±interquartile range (IQR, 25th and 75th percentile). Culture results were calculated 
for the whole right lung and PCR results for 8 μl of DNA extract. * P=0.026. 
Simvastatin treatment of mice did not lower the serum lipid levels of either triglyc-
erides or total cholesterol. The high-fat diet caused a rise of the serum lipid levels. (IV, 
Table 1). 
4.4.2 Immunomodulatory effect of simvastatin treatment (IV) 
In the sera of infected mice, a moderate increase in the concentrations of acute phase pro-
teins was seen. Both SAA and LBP levels started to rise at day 3 p.i. and were highest at 
day 6 p.i.. The increase of SAA was over 200-fold and that of LBP about 10-fold. Toward 
the days 14-20 p.i., the levels returned to the baseline. Simvastatin treatment did not af-
fect the levels significantly. 
Simvastatin treatment did not affect the C. pneumoniae-specific IgG antibody re-
sponse, either. There was, however, a slight increase in the levels in the high-fat mouse 
group, but the background levels in the sera of the mice on a high-fat diet were already 
significantly higher at the beginning of the experiment compared to those in the sera of 
the mice on a regular diet, and the finding was thus considered an artefact (increased tur-
bidity of lipemic sera). In the lungs, the effect of simvastatin treatment on the course of 
infection was seen as an increase of mononuclear cell infiltrates (IV, Fig. 2). In the mice 
fed a regular diet, at each time point, there was a slight increase in these infiltrates due to 
the simvastatin treatment compared to the vehicle-treated mice, and an increase in the 
infiltrates due to the simvastatin treatment was also seen in the mice on a high-fat diet. 
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5 Discussion 
5.1 Technical considerations of the C. pneumoniae mouse model 
In C. pneumoniae mouse models, CO2, ketamine+xylazine, and methoxyflurane have 
mostly been used as anesthetizing agents. Two different anesthetics, CO2 and methoxy-
flurane, were compared here in inoculating mice i.n. with C. pneumoniae. The use of 
methoxyflurane led to a more consistent distribution of bacteria in the respiratory tract in 
individual mice and to higher chlamydial titers. Interestingly, in a pneumococcal pneu-
monia mouse model, too, the use of inhaled anesthetics, methoxyflurane or halothane, in 
i.n. infection led to higher bacterial counts in the lungs compared to anesthesia with an 
i.p. injection of pentobarbital (Rubins and Charboneau, 2000). That study further showed 
differences in the levels of pro-inflammatory cytokines, which were not assessed in the 
present study. The depth of anesthesia was easily controlled with methoxyflurane, and the 
mice breathed normally without gasping, which is frequently seen during CO2 anesthesia. 
CO2-anesthetized mice showed more variation in culture positivity. However, the high 
antibody levels also seen in culture-negative mice, both CO2- and methoxyflurane-
anesthetized, indicate that they have all become infected with chlamydia (data not 
shown). Thus, it is possible that, due to incomplete anesthesia with CO2 in some mice, 
most of the chlamydial inoculum may have remained in the upper respiratory tract, and 
too few organisms may have entered the lung to be detected with lung tissue culture. 
When chlamydiae are grown in different hosts and tissues, the composition and infec-
tivity of the chlamydial preparations is affected (Kuo et al., 1975; Kordova et al., 1977; 
Allan and Pearce, 1979; Neuman et al., 1980). As demonstrated in early human vaccina-
tion trials with C. trachomatis, and later in monkeys (MacDonald et al., 1984; Grayston 
et al., 1985), vaccination with whole organisms led to a more exaggerated disease during 
a natural C. trachomatis infection compared to nonvaccinated subjects. Although the vac-
cine preparations used in the above studies may have contained host components, the 
exaggerated disease after repeated chlamydial infections has been well documented later. 
The crude chlamydial preparations used in most mouse studies certainly contain more 
cellular contaminants than vaccine preparations, but based on the results of the present 
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study, the main factors associated with exaggerated pathology in the present C. pneumo-
niae mouse model are not those included in the host cell components. When mice were 
i.n. mock-inoculated with cellular components alone, mild inflammation was detected in 
the mouse lungs. In BALB/c mice, i.n. inoculation with cell components has also been 
reported to induce only mild histological changes in the lungs (Stack et al., 2000), but no 
IL-12, IFN-γ, TNF-α, IL-10, or IL-4 production (Geng et al., 2000a). In the present study, 
IgG antibodies against mHsp60 were not produced after mock inoculation. However, the 
cellular preparation consisted of HL cell components, and HL is a cell line of human ori-
gin. Thus, no mHsp60 antibodies were expected to be produced, although there is high 
sequence identity between the conserved epitopes of mHsp60 and hHsp60s to allow 
cross-reaction between these and mammalian Hsp60s. Instead, the mock inoculation may 
have induced local antibody production against the cellular components, and the reinocu-
lation with the crude chlamydial preparation may have activated the immunological 
memory mechanisms against cell components, because a partial, although low, protective 
effect against consecutive C. pneumoniae infection was detected. The protection was also 
seen in histology. 
An important finding was the reactivation of culture-negative C. pneumoniae infection 
with a cellular mock preparation. In this mouse model, after i.n. inoculation of the mice 
with a C. pneumoniae challenge dose containing approximately 106 IFUs, the lungs of 
NIH/S mice usually only remain culture-positive for 30 days p.i.. However, it has been 
shown earlier that a culture-negative persistent infection in the lungs can be reactivated as 
culture-positive by immunosuppressive cortisone treatment (Malinverni et al., 1995a; Laiti-
nen et al., 1996). A boosting effect of C. trachomatis infection on C. pneumoniae IgG lev-
els, but not cultures, after two C. pneumoniae infections in primates has been reported 
(Holland et al., 1990). Mock reactivation importantly indicates that a latent infection can be 
reactivated by environmental stimuli in addition to immunosuppression with cortisone. In-
termittent detection of C. pneumoniae is frequently seen in animal models with prolonged 
follow-up times (Moazed et al., 1997). In humans, too, periods of PCR positivity and PCR 
negativity have been reported (Falck et al., 1996). In addition, C. pneumoniae IgA reactiva-
tion has been associated with inflammation in the airways in acute asthma (Wark et al., 
2002). On the other hand, it is also possible that no reactivation actually took place here, but 
that the chlamydia had remained viable for 34 days after the primary infection, and the cul-
ture positivity merely reflected the prolonged primary infection. 
5.2 Aspects of C. pneumoniae pulmonary infection and inflammation 
Though C. pneumoniae strains possess only one serotype, antigenic variation and differ-
ential expression of surface proteins occur (Black et al., 1991; Christiansen et al., 1999). 
Possible microbial polymorphism concerning the virulence of C. pneumoniae strains is 
still not well known. In mouse models, parallel comparison of isolates has shown differ-
ent infection courses between isolates (Kaukoranta-Tolvanen et al., 1993). In the present 
study, a difference between two Finnish C. pneumoniae isolates, K6 and K7, in the re-
covery of viable organisms from lung tissue of NIH/S mice was demonstrated. This could 
be due to the small structural differences between the isolates. On the other hand, K6 and 
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K7 were isolated from consecutive patients during a C. pneumoniae epidemic in Finland, 
and they have been propagated in HL cells, suggesting that the isolates are closely re-
lated, and that some other factors such as the number of passages may be involved. The 
two isolates have not been sequenced. Thus, the conclusions concerning the possible 
structural or other genetic differences between the two isolates and the consequences on 
the course of infection are not proven but inconclusive. In addition, we do not know yet if 
these two Finnish isolates harbor the already identified atherogenic properties or have as 
yet unidentified ones. And several hypothetical proteins without known function and ho-
mologs in other organisms exist in C. pneumoniae, but have not yet been characterized. 
C. pneumoniae disseminates into different organs after i.n., i.v., and s.c. inoculation of 
experimental animals. In primates, C. pneumoniae is detectable in the rectum of animals 
infected into the conjuctiva or nasopharynx (Holland et al., 1990). In the intestinal muco-
sal biopsies in humans, too, C. pneumoniae can be detected with PCR (Chen et al., 2002). 
The i.g. challenging route for C. pneumoniae in animal models has not been reported 
earlier, but C. trachomatis MoPn (C. muridarum), a mouse pathogen, is able to cause a 
persistent gastrointestinal infection/colonization in mouse (Igietseme et al., 2001). When 
the infectious challenge was given to the mice i.g. here, C. pneumoniae DNA could be 
detected in their liver and lungs. In addition, inflammation (lung histology, IL-10 levels) 
and a humoral immune response against C. pneumoniae (serum IgG) could be demon-
strated. Contrary to C. trachomatis MoPn, which is able to cause a persistent gastrointes-
tinal infection/colonization in mouse (Igietseme et al., 2001), viable chlamydiae could not 
be cultured from rectal swabs. It is, indeed, possible that there were too few viable chla-
mydiae in the gastrointestinal tract to be detected by culture from the rectum. This culture 
negativity of rectal swabs in the present study indicates that no autoinoculation took 
place. Development of peribronchial and perivascular mononuclear cellular infiltrates 
could indicate either the development of pulmonary infection with actively replicating C. 
pneumoniae in the lungs or the recruitment of homing lymphocytes into distinct mucosal 
sites, e.g. the lungs, as a function of the common mucosal system and without active 
pulmonary infection (Quiding-Jarbrink et al., 1997). 
In C57BL/6J mice, repeated challenges with C. pneumoniae K7 led to persistent infec-
tion, as demonstrated by PCR and histology. DNA was present in lung tissue with vari-
able PCR positivity rates, suggesting the insidious nature of infection or the difficulty of 
recovering C. pneumoniae DNA uniformly from tissue samples (Chernesky et al., 2002). 
The mice on a cholesterol-enriched diet had slightly increased PCR positivity in their 
heart and lung at early time points, but this effect was lost and even reversed at later time 
points. Previously, atherogenic high-cholesterol diet has been shown to increase the pres-
ence of C. pneumoniae antigen in the aorta of mice (Hu et al., 1999). The effect of cho-
lesterol feeding on C. pneumoniae-induced pulmonary inflammation has not been re-
ported earlier, though other mouse models have shown that hypercholesterolemia impairs 
innate immunity, suppresses T cell responses, hence increasing infectious mortality 
(Roselaar and Daugherty, 1998; Ludewig et al., 2001), as well as changes the Th1/Th2 
balance during the development of atherosclerotic lesions in ApoE-deficient mice (Zhou 
et al., 1998). In the present study, the pulmonary inflammation in repeatedly infected 
mice was slightly intensified by a cholesterol-enriched diet during the first reinfection 
and in the acute phase (4-8 weeks) of the second reinfection. Thus, even though the mice 
in the present study were not overtly hypercholesterolemic, the findings suggest that even 
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a small cholesterol increment in the diet has deleterious effects on the course and im-
munopathology of C. pneumoniae infection. 
5.3 Chlamydial infection and induction of immune response against 
Hsp60s 
A clear IgG antibody response against C. pneumoniae Hsp60 developed in infected 
NIH/S mice, and the levels correlated with those against whole EBs. No comparisons 
with the severity of infection (culture or pulmonary inflammation) could be performed 
due to the small group sizes. In a C. trachomatis monkey model, the persistence of 
cHsp60 antibodies correlated with chlamydial presence, and further, high levels corre-
lated with more severe pathology (Peeling et al., 1999). 
Importantly, autoantibodies against self-Hsp60 also developed in the mice of the pre-
sent study. Subcutaneous immunization of mice with heat-inactivated Mycobacterium 
tuberculosis or mbHsp65 has been found to induce formation of antibodies reacting with 
mbHsp65 and to accelerate atherosclerosis (George et al., 1999; Afek et al., 2000; George 
et al., 2000). Furthermore, the immunization of LDL receptor-deficient mice with oval-
bumin (OVA) fed a cholesterol-enriched diet has also been shown to increase the levels 
of antibodies to mbHsp65 (Maron et al., 2002). Recently, microbial Hsp60/65 (E. coli
GroEL, cHsp60 and mbHsp65) antibodies have been shown to bind to certain hHsp60 
epitopes, which are detected in apparently normal arterial walls but even more abun-
dantly in atherosclerotic arterial walls (Perschinka et al., 2003). Interestingly, elevated 
mHsp60 antibody levels were seen in mice primarily infected with C. pneumoniae and 
then challenged with either C. pneumoniae or mock (cell remnants), which suggests that 
the primary C. pneumoniae infection had primed the mice for the booster effect of the 
infection or the mock inoculation. High mHsp60 IgG levels were demonstrated in mice 
with high C. pneumoniae Hsp60 IgG levels, but not all of the mice with high cHsp60 IgG 
levels exhibited high mHsp60 levels. In C57BL/6J mice, too, the mHsp60-reactive IgG 
antibody levels were elevated after the second exposure to C. pneumoniae, regardless of 
diet, suggesting that the first infection had primed the mice to elicit a response to the host 
Hsp60 protein. Compared to the transient increase in mHsp60 antibodies induced by the 
cholesterol-enriched diet alone, the autoantibody response was prolonged when induced 
by C. pneumoniae infection. In the present study, C57BL/6J mice did not have equally 
high levels of mHsp60 IgG antibodies as NIH/S mice. Indeed, C57BL/6J has been shown 
to be a low responder to chlamydial Hsp60 and 70 proteins (Zhong and Brunham, 1992). 
Repeated microbial exposures starting early in life are suggested to be the reason for the 
generation of antibodies capable of reacting with self-epitopes in Hsps. In pathogen-free 
animals, self-reactive Hsp antibodies do not naturally occur (Grandia et al., 1991). 
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5.4 Atherosclerosis in the chronic C. pneumoniae infection model of 
C57BL/6J mice   
The C57BL/6J mice repeatedly challenged with C. pneumoniae were chronically infected 
with C. pneumoniae, as shown by their persistent lung inflammation and the PCR positiv-
ity of different tissues for C. pneumoniae. The early lipid lesions, which were scattered 
focally in the subendothelium at the base of valve cusps in C57BL/6J mice, were signifi-
cantly increased by C. pneumoniae infections. Indeed, lipid lesions of this kind bear some 
similarity to the earliest stages of atherosclerotic lesion development in human subjects 
(Ross, 1999). Previous mouse studies have shown that C. pneumoniae infection leads to 
accelerated atherosclerosis in C57BL/6J mice only if the mice are hypercholesterolemic, 
and further, only if the hypercholesterolemia has been inititated prior or simultaneously to 
the first C. pneumoniae challenge (Moazed et al., 1997; Blessing et al., 2000; Blessing et 
al., 2001; Blessing et al., 2002a). In the above studies, however, the low-fat diet with only 
cholesterol supplementation was not studied. In the present study, the feeding of mice 
with a 0.2 % cholesterol-supplemented diet was initiated two weeks prior to the first C.
pneumoniae challenge, but the cholesterol homeostasis in circulation was not markedly 
affected, nor was hypercholesterolemia induced with this diet. The distribution of choles-
terol between the lipoprotein subclasses (i.e. levels of VLDL, LDL, and HDL) was not 
studied. If there had been even minor changes, the data might have produced relevant 
information. In the cholesterol-supplemented diet, the total fat content was identical to 
that of the regular chow diet (4 %) used. Further, the diet did not contain a cholate sup-
plement, which contributes to the elevation of cholesterol levels in the circulation of 
C57BL/6J mice, and which was included in the diets of the previous studies with hyper-
cholesterolemic mice (Vergnes et al., 2003). It is essential in C57BL/6 mice to suppress 
hepatic sterol-7-hydroxylase (CYP7A1) by cholate, the major regulator of the synthesis 
of bile acid from cholesterol (Dueland et al., 1993), whose overexpression diminishes the 
progression of atherosclerosis induced by an atherogenic diet (Miyake et al., 2002). Thus, 
the present study suggests that a cholesterol increment in the diet, although not associated 
with changes in plasma total cholesterol, is needed for the accelerated development in-
duced by the infectious burden (i.e. persistent C. pneumoniae infection here). The choles-
terol and cholate components of an atherogenic diet have been shown in C57BL/6J mice 
to induce the expression of genes involved in the proatherogenic inflammatory responses, 
such as acute inflammatory response and fibrinogenesis (Vergnes et al., 2003). Interest-
ingly, dietary cholesterol, without cholate, is critical in the activation of acute inflamma-
tory genes in C57BL/6J mice (Vergnes et al., 2003). As was shown in the present study, 
the dietary cholesterol-supplement exaggerated the C. pneumoniae pulmonary infection 
in C57BL/6J mice. The mechanisms leading to this remain to be studied. 
The effects of repeated C. pneumoniae infections on serum lipid levels were, in 
agreement with the previous studies, virtually absent in C57BL/6J mice on both diets at 
the time points studied several weeks after the C. pneumoniae challenges (Blessing et al., 
2001). In the acute phase of C. pneumoniae infection, changes in lipid levels are present 
in NIH/S mice, and may thus also be present in C57BL/6J mice (Tiirola et al., 2002). 
Also in agreement with the previous studies is the finding that C.pneumoniae infections 
do not induce atherosclerosis in C57BL/6J mice without a modification of diet (Moazed 
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et al., 1999; Blessing et al., 2000). The development of autoimmunity to mHsp60, as pre-
viously proposed by Wick and coworkers, may have participated in the development of 
early atherosclerotic lesions. 
5.5 Antichlamydial effect of simvastatin 
In a wider sense, statins, i.e. the lipid-lowering inhibitors of cholesterol biosynthesis, may 
act as inhibitors of intracellular signaling in eucaryotic cells and in the procaryotes that 
have HMG-CoA reductase of their own. The present study showed that the treatment of 
mice with lipophilic simvastatin at a dose corresponding to the therapeutic dose for treat-
ing hypercholesterolemia in humans (0.5 mg/kg) affected the course of acute C. pneumo-
niae infection by decreasing chlamydial counts and C. pneumoniae DNA in the lungs 
during the early phases of the infection. The present study does not allow interpretations 
of the long-term effects of statin treatment on the persistence of C. pneumoniae infection, 
which is considered important for the development of atherosclerosis. 
The observed anti-chlamydial effect of simvastatin could have been mediated through 
a disturbance in the intracellular trafficking of cholesterol (Kempen et al., 1991; Keidar et 
al., 1994). Chlamydiae, and another gram-negative bacterium, Salmonella, which are 
inhibited by statin treatment (Kothe et al., 2000; Catron et al., 2004), do not have the ca-
pacity to synthesize cholesterol, but cholesterol is required for their successful multiplica-
tion in the intracellular compartment (Lange et al., 2000; Carabeo et al., 2003; Catron et 
al., 2004). Chlamydiae may use cholesterol of the infected cells, derived from either the 
extracellular space, like that derived from LDL uptake, or the intracellular cholesterol 
stores from de novo synthesis (Carabeo et al., 2003). An important step where statins may 
interfere with chlamydial infection is the chlamydial entry into cells, as in the case of 
HIV infection (del Real et al., 2004). Detergent-resistant lipid microdomains in the 
plasma membrane, caveolae, or lipid rafts are rich in cholesterol, and these domains have 
been shown to be important for the entry of several Chlamydia species and biovars, in-
cluding C. pneumoniae (Stuart et al., 2003). The statin may have taken over numerous 
biochemical functions of host cell, which are important for chlamydial infection, through 
inhibition of isoprenoid biosynthesis (Kothe et al., 2000). 
This inhibition may also be partly immune-mediated. In the present study, the pulmo-
nary inflammatory response to C. pneumoniae infection was – opposite to most pre-
existing literature reports - increased by the statin treatment of mice on both diets. The 
anti-inflammatory action that statins exhibit has been reported in several studies con-
ducted in different experimental conditions. In one mouse model, oral administration of 
simvastatin to mice inhibited innate immunity by reducing the oedema (influx of poly-
morphonuclear leukocytes) of a carrageenan-induced inflammatory reaction in the mouse 
foot pad (Sparrow et al., 2001). In another study, atorvastatin diminished histological 
changes in Th1-mediated central nervous system autoimmune disease by promoting Th2 
type immunity and resting Th1 type immunity, which resulted in decreased IFN-
γ secretion among other things (Youssef et al., 2002). Airway inflammation in an OVA-
induced asthma model has also been reported to be decreased by simvastatin treatment 
(McKay et al., 2004). Another group has further demonstrated that pravastatin treatment 
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of OVA-challenged mice reduces total cell counts and eosinophils, but not neutrophils, 
lymphocytes, or macrophages in the lungs (Yeh and Huang, 2004). A common feature of 
all these studies is the use of noninfectious inflammatory stimuli. The present study is the 
first to focus on the effect of statin treatment on immunological parameters after an active 
infection caused by a live, replicating pathogen in vivo under controlled experimental 
conditions. Kiener et al previously pointed out the proinflammatory effects of statins. 
Pretreatment of mice with simvastatin before an inflammatory challenge with thioglycol-
late transiently increased the influx of inflammatory cells into the peritoneal cavity 
(Kiener et al., 2001). In the present study, the increased inflammatory response may re-
flect the intensified reaction, which would be beneficial in defense against the invading 
pathogen. Statins also induce apoptosis, and thus, in simvastatin treated mice, C. pneu-
moniae liberated from infected cells after apoptosis could have been more extensively 
exposed to immune defense. In general, SAA levels parallel those of CRP. SAA binds to 
HDL and may affect cholesterol metabolism and also contribute to the oxidation of LDL 
(reviewed in (Gabay and Kushner, 1999)). In the present study, both SAA and LBP levels 
increased moderately and returned to baseline, but simvastatin therapy did not modulate 
this acute phase response during primary infection. 
In mice, a cholesterol-lowering effect of statins has been achieved with high treatment 
doses even in individuals lacking functional low-density lipoprotein receptors (Bisgaier et 
al., 1997). However, with the simvastatin dose used in the present study, no decrease in 
the total cholesterol or triglyceride levels either in the mice on a regular diet or in those 
on a high-fat diet was seen. The response to a high-fat diet was as expected, and elevated 
levels of serum total cholesterol and triglycerides were observed. 
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6 Conclusions and future prospects 
The present study highlighted the importance of the appropriate performance of the infec-
tious challenge by comparing the different anesthetic agents used to inoculate animals. It 
also showed that the host cell debris in C. pneumoniae inoculum may possibly have some 
contribution to the infection model: inoculation with host cell debris alone induced a 
weak inflammatory response and reactivated culture-negative C. pneumoniae infection in 
the lungs. 
When investigating the lung histopathology of mice infected via different routes, it 
turned out that either C. pneumoniae was able to disseminate from the gastrointestinal 
tract into the lungs through circulation and/or lymphatics or the lymphocytes that had 
encountered gastrointestinal tract-derived C. pneumoniae were homing into the lungs. 
When two different Finnish C. pneumoniae isolates, K6 and K7, were used in parallel 
in the present study, the courses of pulmonary infection differed slightly. 
The present results further indicated that repeated inoculations led to the development 
of a Hsp60 autoimmune response, and further, without overt hypercholesterolemia, re-
peated C. pneumoniae infections enhanced the development of early atherosclerosis le-
sions, offering an experimental model to study chronic C. pneumoniae infection and early 
atherosclerotic events. It was also shown that cholesterol feeding alone transiently in-
creased Hsp60 autoimmune antibodies, but when it was combined with repeated C.
pneumoniae infections, a stronger response developed than with either C. pneumoniae or 
cholesterol feeding alone. Thus, even a small increment of dietary cholesterol alone may 
induce the formation of antibodies to mHsp60, but for persistent Hsp60 autoimmunity, 
the presence of cHsp60 in the stressed cells may possibly also be needed. Further, the 
chronic pulmonary inflammation due to C. pneumoniae was shown to be exaggerated in 
mice on a cholesterol-supplemented diet. 
In the present study, treatment of mice with simvastatin decreased chlamydial growth, 
as has been seen in previous in vitro studies using cerivastatin. The statin used in the pre-
sent study is lipophilic, like cerivastatin, and thus able to access cells in which C. pneu-
moniae is able to multiply. Simvastatin treatment also exerted an immunomodulatory 
effect, but an unexpected one, by increasing the amount of inflammatory cells in lungs. 
Further questions arise from the present findings. A cellular preparation consisting 
only of host cells was shown to reactivate quiescent C. pneumoniae infection in the lungs. 
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We can speculate that other microbial infections or any immunological stimulus might 
also have a similar reactivating effect on chronic infection, thus accelerating the devel-
opment of chronic sequelae such as atherosclerosis. Further animal studies using other 
microbial challenges after established chronic C. pneumoniae infection are needed to find 
answers to these questions. 
The experimental C. pneumoniae mouse models developed to study infection-induced 
atherosclerosis are still poorly characterized. The application of genomics and proteomics 
to study microbe-host interaction during the development of chronic infection in mouse 
models will provide valuable information and allow comparisons with C. pneumoniae
infection in human. 
The interesting finding on the antichlamydial effect of simvastatin in acute infection 
should be expanded to a chronic infection model as well as to studies on the markers of 
systemic inflammation during chronic C. pneumoniae infection. These studies will hope-
fully provide us with the information of whether the beneficial effect of statins on cardio-
vascular diseases may, at least partly, be explained by their antichlamydial (and more 
generally, antimicrobial) effects. 
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